sr141716 has been researched along with Obesity in 347 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 244 (70.32) | 29.6817 |
| 2010's | 100 (28.82) | 24.3611 |
| 2020's | 3 (0.86) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Doss, GA; Finke, PE; Fong, TM; Lao, JZ; Mills, SG; Plummer, CW; Schaeffer, MT; Shearman, LP; Shen, CP; Strack, AM; Stribling, DS; Tong, X; Van der Ploeg, LH; Wang, J | 1 |
| Brown, SE; Choi, S; Fan, J; Fathi, Z; Jenkins, S; Kluender, HC; Konkar, A; Lavoie, R; Mays, R; Natoli, J; O'Connor, SJ; Ortiz, AA; Podlogar, B; Smith, RA; Taing, C; Tomlinson, S; Tritto, T; Zhang, Z | 1 |
| Feng, Y; Fong, TM; Goulet, MT; Hagmann, WK; Jewell, JP; Kumar, S; Lanza, TJ; Lao, J; Lin, LS; Liu, P; Marsh, DJ; Qi, H; Rosko, K; Samuel, K; Shah, SK; Shearman, LP; Shen, CP; Strack, A; Stribling, DS; Tong, X; Van der Ploeg, LH; Wang, J; Xiao, JC; Xu, SS; Yin, W | 1 |
| Achebe, F; Akuche, C; Brown, SE; Choi, S; Fan, J; Fathi, Z; Jenkins, S; Kluender, HC; Konkar, A; Lavoie, R; Mays, R; Natoli, J; O'Connor, SJ; Ortiz, AA; Smith, RA; Su, N; Taing, C; Tomlinson, S; Tritto, T; Wang, G; Wirtz, SN; Wong, W; Yang, XF; Ying, S; Zhang, Z | 1 |
| Alig, L; Alsenz, J; Andjelkovic, M; Bénardeau, A; Bendels, S; Bleicher, K; Bourson, A; David-Pierson, P; Guba, W; Hildbrand, S; Kube, D; Lübbers, T; Mayweg, AV; Narquizian, R; Neidhart, W; Nettekoven, M; Plancher, JM; Rocha, C; Rogers-Evans, M; Röver, S; Schneider, G; Taylor, S; Waldmeier, P | 1 |
| Beers, DS; Brodbeck, RM; Chenard, BL; Guo, Q; Hammer, J; Hutchison, AJ; Kershaw, M; Krause, JE; Mao, J; Maynard, GD; Near, KE; Wustrow, DJ; Yuan, J; Zhao, H; Zhou, D | 1 |
| Chang, CH; Jung, ME; Kang, SY; Kim, J; Kim, MA; Lee, J; Lee, SH; Na, J; Park, HJ; Park, JH; Seo, HJ; Song, KS; Yoo, J; Yun, H | 1 |
| Ahn, K; Jung, ME; Kim, J; Kim, JY; Lee, J; Lee, SH; Seo, HJ | 1 |
| Alam, S; Hou, DR; Hung, MS; Kuan, TC; Lin, TP; Ramanathan, M | 1 |
| Jung, ME; Kang, SY; Kim, J; Kim, MJ; Lee, J; Lee, SH; Seo, HJ; Song, KS | 1 |
| Gupta, S; Jain, MR; Joharapurkar, A; Kapadnis, P; Kshirsagar, S; Mishra, B; Mitra, P; Pandya, P; Patel, H; Patel, JZ; Patel, PR; Sadhwani, N; Solanki, M; Soni, R; Srivastava, BK; Takale, V | 1 |
| Black, SC; Carpino, PA; DaSilva-Jardine, P; Dow, RL; Griffith, DA; Hadcock, JR; Iredale, PA; Nduaka, CI; O'Connor, RE; Paight, ES; Schneider, SR; Scott, DO | 1 |
| Benwell, K; Brooks, TD; Foloppe, N; Kennett, G; Knight, AR; Misra, A; Monck, NJ | 1 |
| Boström, J; Cheng, L; Greasley, PJ; Hjorth, S; Nordberg, H; Olsson, RI; Ryberg, E; Tholander, J | 1 |
| Bjurling, E; Cooper, M; Högberg, T; Linget, JM; Murray, A; Nielsen, PA; Nørregaard, PK; Receveur, JM | 1 |
| Boykow, GC; Chackalamannil, S; Duffy, RA; Greenlee, WJ; Jayne, CL; Kowalski, TJ; Lachowicz, JE; Li, SW; Miller, MW; Scott, JD; Spar, BD; Stamford, AW; Wang, H; Xia, Y | 1 |
| Han, HK; Jung, ME; Kang, SY; Kim, J; Kim, MJ; Kim, MS; Lee, J; Lee, M; Lee, SH; Seo, HJ; Son, EJ; Song, KS | 1 |
| Baker, J; Cowley, P; Edwards, D; Ho, KK; Jokiel, P; Letourneau, JJ; McAleer, L; Ohlmeyer, MH; Olson, J; Riviello, CM; Swanson, RN; Ward, N; Webb, ML; Yang, J | 1 |
| Behnia, K; Carlson, KE; Ewing, WR; Gu, Z; Hong, Y; Johnghar, S; Keim, WJ; Miller, KJ; Murugesan, N; O'Tanyi, E; Pelleymounter, MA; Rohrbach, KW; Tian, Y; Yang, Y; Zhu, Y | 1 |
| Chorvat, RJ | 1 |
| Ahmad, S; Azzara, AV; Bisaha, S; Devenny, J; Flynn, N; Gemzik, B; Glick, S; Godonis, H; Harvey, S; Hernandez, AS; Huang, C; Janovitz, EB; Longhi, D; Murphy, BJ; Ngu, K; Pelleymounter, MA; Robl, JA; Rohrbach, K; Rooney, S; Thomas, M; Wang, W; Washburn, WN; Zhang, H; Zhang, L | 1 |
| Abdalla, J; Cinar, R; Coffey, NJ; Hassan, SA; Iyer, MR; Katz, A; Kim, KA; Lee, YS; Liu, Z; Wood, CM; Zawatsky, CN | 1 |
| Blumen, T; Brake, R; Cohen, Y; Ferreira, S; Kolodziej, A; Morningstar, M | 1 |
| Ausseil, J; Briand-Mésange, F; Chap, H; Salles, J; Salles, JP; Trudel, S | 1 |
| Chen, B; Hu, N | 1 |
| Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T | 1 |
| Chitrala, KN; Enos, RT; Ganewatta, MS; McCellan, J; Mehrpouya-Bahrami, P; Murphy, EA; Nagarkatti, M; Nagarkatti, P; Tang, C; Velazquez, KT | 1 |
| Choi, CS; Han, JH; Kim, IY; Kim, JE; Kim, KW; Kim, W; Lee, EK; Lee, YJ; Park, JH; Rho, JG; Seong, JK; Shin, H; Son, DH; Song, BJ; Yoon, J; Yoon, SG | 1 |
| Brissard, L; Degrace, P; Demizieux, L; Hichami, A; Khan, NA; Leemput, J; Maquart, G; Passilly-Degrace, P | 1 |
| Bae, SH; Chang, E; Kim, DH; Lee, DH; Park, CY; Yang, H | 1 |
| Fu, L; Gu, CW; Han, JH; Wei, LW; Yuan, ZQ; Zhao, MD | 1 |
| Han, JH; Kim, KW; Kim, W; Park, JY; Rho, JG; Seong, JK; Shin, H; Son, DH; Yoon, SH | 1 |
| Mehrpouya-Bahrami, P; Miranda, K; Nagarkatti, M; Nagarkatti, PS; Singh, NP; Zumbrun, EE | 1 |
| Friedman, JM; Li, Z; Schmidt, SF | 1 |
| Chen, W; Chen, Z; Li, S; Wang, L; Xue, N; Zheng, Z | 1 |
| Bajza, A; Literáti-Nagy, B; Literati-Nagy, Z; Mandl, J; Szilvássy, Z; Tory, K; Vígh, L | 1 |
| Casu, MA; Lazzari, P; Marcello, S; Mastinu, A; Murineddu, G; Pinna, GA; Pira, M; Pisu, C; Reali, R | 1 |
| Bhandari, U; Khanna, G; Kumar, V; Tripathi, CD | 1 |
| Bhanot, S; Chakravarty, K; Manchem, VP; McCaleb, ML; Monia, BP; Watts, LM; Yu, XX | 1 |
| Baretić, M | 1 |
| Cinar, R; Earley, BJ; Godlewski, G; Jourdan, T; Kunos, G; Szanda, G; Tam, J; Zhou, L | 1 |
| Buckley, JL; Rasmussen, EB | 1 |
| Kuk, AY; Nott, DJ; Yang, Y | 1 |
| Berbée, JF; Boon, MR; Guigas, B; Havekes, LM; Jukema, JW; Kooijman, S; Lombès, M; Meijer, OC; Pelgrom, LR; Rensen, PC; Sips, HC; Tamsma, JT; van Aggele, RC; van Dam, AD; van den Hoek, AM; Visseren, CA | 1 |
| Bahekar, R; Jain, MR; Joharapurkar, AA; Kshirsagar, SG; Patel, KN; Patel, V; Srivastava, BK | 1 |
| Chang, CP; Chao, YS; Chen, PH; Hsiao, WC; Hung, MS; Lin, Y; Shia, KS; Wang, YT; Wu, CH; Yeh, YN | 1 |
| Lockie, SH; Oldfield, BJ; Stefanidis, A; Tschöp, MH | 1 |
| Dopart, R; Kendall, DA; Lu, D | 1 |
| Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Elshewehy, AM; Kilpatrick, ES; Sathyapalan, T | 1 |
| Atkin, SL; Coady, AM; Javed, Z; Kilpatrick, ES; Sathyapalan, T | 1 |
| Barnett, A; Rahim, A; Samat, A | 1 |
| Paquot, N; Scheen, AJ | 2 |
| Noll, G; Périat, D; Sudano, I | 1 |
| Kintscher, U | 1 |
| Kruse, CG; Lange, JH | 1 |
| Michaelides, M; Piyis, YK; Ramalhete, RC; Thanos, PK; Volkow, ND; Wang, GJ | 1 |
| Chatterjee, T; Ince, H; Nienaber, ChA; Rehders, TC; Ritz, A | 1 |
| Piomelli, D | 1 |
| Dora, JM; Scheffel, RS | 1 |
| Chaput, JP; Tremblay, A | 1 |
| Di Marzo, V | 2 |
| Deedwania, P | 1 |
| Caldwell, C; Fekete, C; Klein, M; Liposits, Z; Nogueiras, R; Reizes, O; Rohner-Jeanrenaud, F; Suchanek, PM; Tschöp, J; Tschöp, MH; Veyrat-Durebex, C; Watanabe, M; Wittmann, G; Woods, SC | 1 |
| Manzato, E; Marchiori, M; Zambon, A | 1 |
| Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V | 1 |
| Doggrell, SA | 3 |
| Basile, I; Gary-Bobo, M; Maynadier, M | 1 |
| Harrison, SA; Kashi, MR; Torres, DM | 1 |
| Narbro, K; Neovius, M | 1 |
| Samat, A; Taheri, S; Thomas, GN; Tomlinson, B | 1 |
| Galzin, AM; Hall, D; Minehira, K; Poussin, C; Tarussio, D; Thorens, B | 1 |
| Chou, CM; Samaha, FF | 1 |
| Jones, D | 1 |
| Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U | 1 |
| Pacher, P | 1 |
| Izumiya, Y; Kaikita, K; Matsuzawa, Y; Miyata, K; Nakayama, M; Nozaki, T; Obata, T; Ogawa, H; Sugamura, K; Sugiyama, S; Takeya, M | 1 |
| Alméras, N; Boka, G; Després, JP; Lemieux, I; Ross, R | 1 |
| Idelevich, E; Kirch, W; Schindler, C | 1 |
| Höcht, C; Mayer, MA; Puyó, A; Taira, CA | 1 |
| Després, JP | 3 |
| Galzin, AM; Guillot, E; Lacombe, A; Lefèvre, AL; Magnan, C; Migrenne, S; Pruniaux, MP | 1 |
| Faludi, G; Halmy, L; Purebl, G; Rihmer, Z | 1 |
| Golay, A; Vincent, M | 1 |
| Lillemoe, KD; Mathur, A; Pitt, HA; Prather, AD; Swartz-Basile, DA; Wade, TE; Wang, S; Zyromski, NJ | 1 |
| Taskinen, MR | 1 |
| Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET | 1 |
| Scheen, AJ | 3 |
| Gorzalka, BB; Hill, MN | 1 |
| Cota, D; D'Alessio, DA; Obici, S; Olivieri, M; Prodi, E; Sandoval, DA; Seeley, RJ; Woods, SC | 1 |
| McPartland, JM | 1 |
| Bergman, RN; Catalano, KJ; Chiu, JD; Harrison, LN; Hsu, IR; Ionut, V; Kabir, M; Kim, SP; Kolka, C; Lottati, M; Mooradian, V; Richey, JM; Stefanovski, D; Woolcott, OO; Zheng, D | 1 |
| Ginsberg, HN; Woods, SC | 1 |
| Kew, ST; Loh, KY | 1 |
| Paris, M | 1 |
| Hu, J; Huang, M; Zhu, C | 1 |
| Atkin, SL; Cho, L; Coady, AM; Kilpatrick, ES; Le Roux, CW; Sathyapalan, T | 1 |
| Alvarez de Sotomayor, M; Callejón Mochón, M; Casto, C; Herrera, MD; Jiménez-Palacios, FJ; Marhuenda, E; Mingorance, C | 1 |
| Bifulco, M; Pisanti, S | 1 |
| Crippa, JA; Moreira, FA | 1 |
| Fong, TM; Heymsfield, SB | 1 |
| Odegaard, K; Persson, U; Willis, M | 1 |
| Corkey, BE; Deeney, JT; Getty-Kaushik, L; Krawczyk, S; Richard, AM; Shirihai, O | 1 |
| Bifulco, M; Laezza, C; Malfitano, AM; Santoro, A | 1 |
| Braakman, HM; de Krom, MC; van Kranen-Mastenbroek, VH; van Oostenbrugge, RJ | 1 |
| Abood, ME; Bai, Y; Barak, LS; Caron, MG; Kapur, A; Sharir, H; Zhao, P | 1 |
| Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES | 1 |
| Bloks, VW; Jonas, I; Koolman, AH; Kuipers, F; Oosterveer, MH; Sauer, PJ; van Dijk, G | 1 |
| Després, JP; Di Marzo, V | 1 |
| Burch, J; Glanville, J; McKenna, C; Norman, G; Palmer, S; Sculpher, M; Woolacott, N | 1 |
| Büning, J; Drenckhan, M; Klein, J; Lehnert, H; Lilienthal, W; Perwitz, N; Ristow, M; Wagner, I; Wenzel, J; Zarse, K | 1 |
| Balaraman, R; Chatterjee, A; Jain, MR; Mohapatra, J; Pandya, G; Patel, PR; Sharma, M; Singh, S | 1 |
| Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A | 1 |
| Cheung, BM; Li, M | 1 |
| Amod, A; Chaudhari, U; Hollander, PA; Litwak, LE | 1 |
| Berrendero, F; Burokas, A; Gispert, JD; Heyne, A; Kiesselbach, C; Maldonado, R; Martín, M; Martín-García, E; Millán, O; Rubí, B | 1 |
| Lockney, J; Maldonado, R; Oveisi, F; Piomelli, D; Touriño, C | 1 |
| Ahn, GJ; Chae, HW; Chae, YN; Choi, SH; Kim, HD; Kim, MK; Kim, SH; Moon, HS; Park, KJ; Shin, CY; Shin, YG; Son, MH; Yang, EK; Yoon, SH | 1 |
| Shwarts, V | 1 |
| Bartels, M; Kis, B; Scherbaum, N; Ugur, T | 1 |
| Degrace, P; Demizieux, L; Djaouti, L; Gresti, J; Jourdan, T; Vergès, B | 1 |
| Ceccaldi, PF; Ducarme, G; Luton, D; Pejoan, H | 1 |
| Cohen, SB; DiPetrillo, K; Xu, L; Zhang, Y | 1 |
| Biemer-Daub, G; Herling, AW; Miranville, A; Voss, MD | 1 |
| Axel, AM; Hansen, G; Hansen, HH; Larsen, PJ; Mikkelsen, JD; Raben, A; Tang-Christensen, M | 1 |
| Giraldo, J | 1 |
| Baldock, PA; Enriquez, RF; Herzog, H; Lee, NJ; Lin, S; Nguyen, AD; Riepler, SJ; Sainsbury, A; Shi, YC; Stehrer, B; Yulyaningsih, E; Zhang, L | 1 |
| Patti, ME | 1 |
| Ambudkar, SV; Bátkai, S; Godlewski, G; Kunos, G; Liu, J; Makriyannis, A; Mukhopadhyay, B; Ohnuma, S; Osei-Hyiaman, D; Pickel, J; Tam, J; Vemuri, VK | 1 |
| Bäckhed, F; Cani, PD; Delzenne, NM; Lambert, DM; Muccioli, GG; Naslain, D; Reigstad, CS | 1 |
| Boekholdt, SM; Peters, RJ | 1 |
| Bhatt, DL; Bousser, MG; Cohen, E; Creager, MA; Despres, JP; Easton, JD; Fox, KA; Gaudin, C; Hamm, CW; Job, B; Montalescot, G; Murphy, JH; Pearson, TA; Steg, PG; Topol, EJ | 1 |
| de Sotomayor, MA; Herrera, MD; Marhuenda, E; Mingorance, C | 1 |
| Ballantyne, CM; Mansoori, A; Perrard, JL; Perrard, XD; Smith, CW; Wang, Q; Wu, H | 1 |
| Cabasino, S; Lazzari, P; Manca, I; Mastinu, A; Pani, L; Sanna, A | 1 |
| Cervino, C; Pagotto, U; Pasquali, R; Vicennati, V | 1 |
| Atkin, SL; Dawson, AJ; Kilpatrick, ES; Mellor, DD; Sathyapalan, T | 1 |
| Christopoulou, FD; Kiortsis, DN | 1 |
| Bricker, LA; Feucht, C; Greydanus, DE | 1 |
| Madsbad, S | 1 |
| Bocquier, A; Bouvenot, G; Bouvenot, J; Cortaredona, S; Jardin, M; Nauleau, S; Sauze, L; Sciortino, V; Verger, P | 1 |
| Bennetzen, MF | 1 |
| Raffa, RB; Ward, SJ | 1 |
| Bagdy, G; Hunyady, L; Juhasz, G; Lazary, J | 1 |
| Acharya, A; Balaraman, R; Chatterjee, A; Jain, MR; Mohapatra, J; Pandya, G; Sharma, M | 1 |
| Christou, GA; Elisaf, MS; Kiortsis, DN; Tellis, CC; Tselepis, AD | 1 |
| Cavallo, JS; Chain, DC; Dressler, HM; Economides, KD; Fan, C; Favara, SG; Galzin, AM; Guillot, E; Naimi, S; Palejwala, VA; Pang, Z; Polites, HG; Pruniaux, MP; Schaffer, E; Tocci, MJ; Weinstock, D; Wu, NN; Yamdagni, P; Zhang, X; Zhao, W | 1 |
| Bornstein, SR; Chavakis, T; Lamounier-Zepter, V; Schindler, C | 1 |
| Bergman, RN; Catalano, KJ; Chiu, JD; Harrison, LN; Hsu, IR; Ionut, V; Iyer, M; Kabir, M; Kim, SP; Lottati, M; Richey, JM; Stefanovski, D; Woolcott, OO; Zheng, D | 1 |
| Chaperon, F; Chen, YA; Commerford, SR; Dardik, B; Gerber, SP; Gromada, J; He, X; Hollenbeck, T; Jacobson, LH; Jaton, AL; Liu, H; McNamara, P; Nguyen-Tran, V; Schwartzkopf, C; Seidel, HM; Teixeira, S | 1 |
| Degrace, P; Demizieux, L; Djaouti, L; Gaba, L; Gresti, J; Jourdan, T; Vergès, B | 1 |
| Boomhower, SR; Buckley, J; Rasmussen, EB; Reilly, W | 1 |
| Abu-Lebdeh, H; Jensen, M; Klein, S; Mundi, M; Smith, SR; Toledo, FG; Triay, J | 1 |
| Clapham, JC; Gamo, Y; Mitchell, SE; Morgan, DG; Sinclair, R; Speakman, JR; Zhang, LN | 1 |
| Abrams, K; Ara, R; Cooper, N; Davies, MJ; Dunkley, A; Gray, LJ; Khunti, K; Sutton, A; Warren, FC | 1 |
| Abrams, K; Ara, R; Blake, L; Cooper, N; Crowther, M; Davies, M; Dunkley, A; Gray, L; Hernández, M; Jackson, R; Khunti, K; Rees, A; Stevenson, M; Sutton, A; Warren, F | 1 |
| Bedros, JR; Medvegy, M; Pados, G; Simonyi, G | 1 |
| Bergman, RN; Catalano, KJ; Chiu, JD; Harrison, LN; Hsu, IR; Ionut, V; Kabir, M; Kim, SP; Kolka, C; Lottati, M; Richey, JM; Stefanoski, D; Woolcott, OO; Zheng, D | 1 |
| Boesten, JE; Kaper, J; Kroon, AA; Stoffers, HE; van Schayck, OC | 1 |
| Ditrói, K; Kleiner, D | 1 |
| Backhouse, K; Bell, JD; Frost, GS; Robertson, MD; Russell-Jones, D; Sarac, I; Shojaee-Moradie, F; Stolinski, M; Thomas, EL; Umpleby, AM; Wright, J | 1 |
| Bagdy, G; Gonda, X; Kirilly, E | 1 |
| Lockie, SH; Oldfield, BJ; Stefanidis, A; Verty, AN | 1 |
| Essawy, S; Zaitone, SA | 1 |
| Colman, E | 1 |
| Berekelya, L; Bernard, L; Brunet, F; Galzin, AM; Gibert, Y; Guillot, E; Laudet, V; Le Bail, JC; Nishio, S; Sánchez, JA; Triqueneaux, G | 1 |
| Lazzari, P; Mastinu, A; Pani, L; Pinna, GA; Pira, M | 1 |
| Chen, D; Liu, X; Shi, Y; Zhang, W | 1 |
| Bunce, S; Heppenstall, C; Smith, JC | 1 |
| Bergholm, R; Hakkarainen, A; Kotronen, A; Lundbom, J; Lundbom, N; Rissanen, A; Santos, A; Sevastianova, K; Tiikkainen, M; Urjansson, M; Yki-Järvinen, H | 1 |
| Brichard, SM; Detry, R; Ge, Q; Gérard, J; Maury, E; Navez, B; Noël, L; Rycken, L | 1 |
| Ahmed, HH; Assaf, N; Salem, NA | 1 |
| Asproni, B; Bottazzi, ME; Curzu, MM; Lazzari, P; Mastinu, A; Murineddu, G; Pau, A; Pinna, G; Pinna, GA; Reali, R; Ruiu, S; Tambaro, S | 1 |
| Kautzky-Willer, A; Lemmens-Gruber, R | 1 |
| Buggy, Y; Egberts, TC; Layton, D; Leufkens, HG; Mantel-Teeuwisse, AK; Straus, SM; Willemen, MJ | 1 |
| Adan, RA; Meye, FJ; Ramakers, GM; Trezza, V; Vanderschuren, LJ | 1 |
| Gasteyger, C; Golay, A; Hanotin, C; Pataky, Z; Rissanen, A; Ziegler, O | 1 |
| Boomhower, SR; Doherty, TS; Rasmussen, EB | 1 |
| Arnone, M; Delgorge, C; Gonalons, N; Keane, P; Maffrand, JP; Ravinet Trillou, C; Soubrie, P | 1 |
| Kirkham, TC | 1 |
| Bensaid, M; Esclangon, A; Gary-Bobo, M; Le Fur, G; Maffrand, JP; Oury-Donat, F; Soubrié, P | 1 |
| Vastag, B | 1 |
| Bouaboula, M; Carrière, D; Casellas, P; Hilairet, S; Le Fur, G | 1 |
| Cota, D; Genghini, S; Pagotto, U; Pasquali, R | 1 |
| Arnone, M; Delgorge, C; Menet, C; Ravinet Trillou, C; Soubrié, P | 1 |
| Allison, DB; Fernandez, JR | 1 |
| Killestein, J; Mathus-Vliegen, EM; Polman, CH; van Oosten, BW | 1 |
| Halford, JC | 1 |
| Connoley, IP; Liu, YL; Stock, MJ; Wilson, CA | 1 |
| Bidouard, JP; Cadrouvele, C; Herbert, JM; Janiak, P; Marniquet, X; O'Connor, SE; Poirier, B; Staels, B | 1 |
| McCain, J | 1 |
| Nutt, D | 1 |
| Heinzl, S | 1 |
| Conti, CR | 1 |
| Clarisse, M; Di Vetta, V; Giusti, V | 1 |
| Bérubé-Parent, S; Chaput, JP; Tremblay, A | 1 |
| Di Marzo, V; Matias, I | 1 |
| Schaerlig, E | 1 |
| Arnone, M; Bribes, E; Buisson, I; Casellas, P; Galiègue, S; Jbilo, O; Le Fur, G; Péleraux, A; Pénarier, G; Ravinet-Trillou, C; Soubrié, P | 1 |
| Kennedy, RL; Khoo, EY | 1 |
| Avorn, J | 1 |
| Wadman, M | 2 |
| Cox, SL | 1 |
| Ducobu, J; Sternon, J | 1 |
| Caruso, MK; Greenway, FL | 1 |
| Després, JP; Golay, A; Sjöström, L | 1 |
| Yanovski, SZ | 1 |
| Shah, S; Tear, S | 1 |
| Astrup, AV; Breum, L; Bruun, JM; Svendsen, OL; Toubro, S | 1 |
| Cheskin, LJ; Sidhaye, A | 1 |
| Marx, J | 1 |
| Golay, A; Makoundou, V | 1 |
| Letonturier, P | 1 |
| Cannon, CP | 1 |
| Vinik, AI | 1 |
| Blackburn, GL; Waltman, BA | 1 |
| Aronne, LJ; Devin, J; Heshmati, HM; Pi-Sunyer, FX; Rosenstock, J | 1 |
| Tonstad, S | 1 |
| Cannon, CP; Gelfand, EV | 2 |
| Gadde, KM | 2 |
| Majumdar, S; Padwal, R | 1 |
| Esposito, K; Giugliano, D | 1 |
| Hamann, A | 2 |
| Horvath, TL | 1 |
| Alméras, N; Després, JP; Lemieux, I | 1 |
| Boyd, ST; Fremming, BA | 1 |
| Behn, A; Ur, E | 1 |
| Halpern, A; Mancini, MC | 1 |
| Benwell, KR; Clifton, PG; Kennett, GA; Misra, A; Revell, DF; Sellwood, DM; Thornton-Jones, ZD; Vickers, SP | 1 |
| Caterson, ID; Finer, N | 1 |
| Allison, DB; Gadde, KM | 1 |
| Cannon, E; Lundquist, LM; Sirimaturos, M | 1 |
| Després, JP; Golay, A; Hanotin, C; Pi-Sunyer, X; Scheen, AJ; Van Gaal, LG | 1 |
| Boss, O; Hofbauer, KG; Nicholson, JR | 1 |
| Heal, DJ | 1 |
| Halford, JC; Harrold, JA; Kirkham, TC; Tucci, SA | 1 |
| Friedrich, MJ | 1 |
| André, C; Curioni, C | 1 |
| Ahmed, MH | 1 |
| Cleland, SJ; Sattar, N | 1 |
| Finer, N; Hollander, P; Jensen, MD; Scheen, AJ; Van Gaal, LF | 1 |
| Wierzbicki, AS | 1 |
| Connell, JM; Ritchie, SA | 1 |
| Henness, S; Lyseng-Williamson, KA; Robinson, DM | 1 |
| Hofbauer, KG; Nicholson, JR | 1 |
| Nau, JY | 1 |
| Fujioka, K | 1 |
| Baraboi, ED; Denis, RG; Deshaies, Y; Doyon, C; Lalonde, J; Richard, D; Samson, P | 1 |
| Korf, HW; Kreutz, S; Schubert-Zsilavecz, M | 1 |
| Kyrou, I; Tsigos, C; Valsamakis, G | 1 |
| Majumdar, SR; Padwal, RS | 1 |
| Rotthoff, T; Scherbaum, WA | 1 |
| Costa, B | 1 |
| Croci, T; Zarini, E | 1 |
| Cervino, C; Pagotto, U; Pasquali, R | 1 |
| Duffy, D; Rader, D | 1 |
| Hollander, P | 1 |
| Dey, SK; Maccarrone, M; Wang, H | 1 |
| Lambert, ML; Roberfroid, D; Vlayen, J | 1 |
| Shapiro, H; Singer, P | 1 |
| Bennett, AJ; Kendall, DA; O'Sullivan, SE; Randall, MD | 1 |
| Roberfroid, D | 1 |
| Patel, PN; Pathak, R | 1 |
| Bifulco, M; Gazzerro, P; Grimaldi, C; Pisanti, S; Santoro, A | 1 |
| Bray, G; Hadley, RD; Henry, RR; Lillo, JL; Woods, SC | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP | 1 |
| Deveaux, V; Hezode, C; Lotersztajn, S; Mallat, A; Teixeira-Clerc, F; Tran van Nhieu, J | 1 |
| Girard, J; Lafontan, M; Piazza, PV | 1 |
| Formiguera, X; Sierra, A | 1 |
| Scheen, AJ; Van Gaal, LF | 2 |
| Del Arco, I; Javier Pavón, F; Macías, M; Perez-Valero, V; Rodríguez de Fonseca, F; Serrano, A | 1 |
| Ardino, EL; Bernstein, Y; Ferrara, JJ; Furjanic, MA; Kim, E; McAndrew, NR; Nagar, S; Ngondara, A; Raffa, RB; Thomas, KJ; Walker, JM; Ward, SJ; Xie, S | 1 |
| Bray, GA; Ryan, DH | 1 |
| Arnone, M; Bensaid, M; Chabbert, M; Croci, T; Cruccioli, N; Elachouri, G; Gallas, JF; Gary-Bobo, M; Herbert, JM; Janiak, P; Lacheretz, F; Le Fur, G; Maffrand, JP; Marini, P; Oury-Donat, F; Pfersdorff, C; Ravinet-Trillou, C; Roque, C; Scatton, B; Soubrié, P | 1 |
| Alemany, M; Cabot, C; Fernández-López, JA; Ferrer-Lorente, R | 1 |
| Bloch, MJ; Bronander, KA | 1 |
| Wirth, A | 1 |
| Traynor, K | 1 |
| Ashton, JC; Smith, PF | 1 |
| Anthenelli, RM | 1 |
| Giusti, V | 1 |
| Jensen, MD | 1 |
| Lillo, JL | 1 |
| Banasch, M; Goetze, O; Meier, JJ; Schmidt, WE | 1 |
| Formiguera, X; Scheen, AJ; Van Gaal, LF | 1 |
| Barbosa, I; Bidouard, JP; Cadrouvele, C; Dedio, J; Gouraud, L; Herbert, JM; Janiak, P; Le Fur, G; Maffrand, JP; O'Connor, S; Pierre, F; Poirier, B | 1 |
| Saavedra, LE | 1 |
| Gargallo, M; Isabel Millán, A; Moreno, B; Rubio, MA | 1 |
| Watson, KE | 1 |
| Bloom, SR; Dhillo, WS; Gardiner, JV; Ghatei, MA; Kennett, GA; Liu, YL; Small, CJ; White, NE | 1 |
| Van Gaal, L | 1 |
| Zieba, R | 1 |
| Käser, L; Kolyvanos, NU; Suter, PM; Vetter, W | 1 |
| Bodary, PF; Eitzman, DT; Iglay, HB | 1 |
| Cannon, CP; Dibble, CT; Gelfand, EV | 1 |
| Astrup, A; Bartels, EM; Bliddal, H; Christensen, R; Kristensen, PK | 1 |
| Woods, SC | 1 |
| Moyer, MP; Robertson, DA; Ward, SG; Wright, KL | 1 |
| Ueda, N; Wang, J | 1 |
| Aronne, LJ; Isoldi, KK | 3 |
| Cannon, CP; Steinberg, BA | 1 |
| Boekholdt, SM; Jukema, JW; Peters, RJ | 1 |
| Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H | 1 |
| McCall, AL | 1 |
| Feinglos, MN; Green, JB | 1 |
| Després, JP; Mancia, G; Pi-Sunyer, X; Ruilope, LM; Scheen, A; Van Gaal, L; Zanchetti, A | 1 |
| Kaila, B; Raman, M | 1 |
| Després, JP; McCarthy, C; Pi-Sunyer, X; Scheen, A; Van Gaal, L | 1 |
| Nilsson, PM | 1 |
| Cota, D | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Forslund, T; Hjemdahl, P; Raaschou, P; Wettermark, B | 1 |
| Després, JP; Pi-Sunyer, X; Scheen, A; Van Gaal, L | 1 |
| Blüher, M | 1 |
| Aronsen, L | 1 |
| Aronne, LJ; Dikkers, C; Wright, SM | 1 |
| Aronne, LJ; Neff, LM | 1 |
| Bhatt, DL; Cannon, CP; Deanfield, JE; Després, JP; Gaudin, C; Hu, B; Job, B; Kapadia, S; Kastelein, JJ; Lincoff, AM; Nicholls, SJ; Nissen, SE; Rodés-Cabau, J; Ruzyllo, W; Steinhubl, SR; Tuzcu, EM; Wolski, K; Yasin, M | 1 |
| Bifulco, M; Gazzerro, P; Laezza, C; Malfitano, AM; Pisanti, S; Santoro, A | 1 |
| Berry, C; Bourassa, MG | 1 |
| Hanotin, C; Rissanen, AM; Rössner, S; Scheen, AJ; Van Gaal, LF; Ziegler, O | 1 |
| Sarzani, R | 1 |
| Arenare, F; Brambilla, G; Grassi, G; Mancia, G; Quarti-Trevano, F; Seravalle, G | 1 |
| Bermúdez-Silva, FJ; de Fonseca, FR; Goya, P; Hernández-Folgado, L; Jagerovic, N; Macías, M; Pavón, FJ; Pérez-Valero, V; Serrano, A | 1 |
| Nogueiras, R; Rohner-Jeanrenaud, F; Tschöp, MH; Woods, SC | 1 |
| Duh, D; Vanddevijver, A | 1 |
| Bátkai, S; Di Marzo, V; Fezza, F; Goparaju, SK; Járai, Z; Kunos, G; Liu, J; Miura, GI; Palmiter, RD; Sugiura, T; Wang, L | 1 |
127 review(s) available for sr141716 and Obesity
| Article | Year |
|---|---|
Peripherally restricted CB1 receptor blockers.
Topics: Animals; Brain; Cocaine; Drug Discovery; Humans; Liver Diseases; Metabolic Diseases; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides | 2013 |
Obesity drug therapy.
Topics: Anti-Obesity Agents; Appetite; Combined Modality Therapy; Comorbidity; Cost-Benefit Analysis; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Combinations; Exercise Therapy; Fructose; Gastrointestinal Hormones; Humans; Incretins; Insulin; Insulin Secretion; Intestines; Lactones; Leptin; Life Style; Models, Biological; Neuropeptides; Obesity; Orlistat; Phentermine; Phytotherapy; Piperidines; Plant Preparations; Pyrazoles; Rimonabant; Topiramate | 2013 |
Pharmacotherapy for obesity in menopausal women.
Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Lactones; Menopause; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Venoms | 2008 |
Inhibitors of cannabinoid receptors and glucose metabolism.
Topics: Animals; Blood Glucose; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Rimonabant | 2008 |
The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Dyslipidemias; Endocannabinoids; Humans; Insulin Resistance; Lipid Metabolism; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Signal Transduction | 2009 |
CB(1) receptor antagonism: biological basis for metabolic effects.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Delivery Systems; Gene Expression Regulation; Homeostasis; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.
Topics: Adiponectin; Adipose Tissue; Animals; Anti-Obesity Agents; Body Fat Distribution; Clinical Trials as Topic; Drug Delivery Systems; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant | 2009 |
Current and emerging therapies in nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics; Comorbidity; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lactones; Life Style; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Weight Loss | 2008 |
Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Cost-Benefit Analysis; Cyclobutanes; Europe; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Quality-Adjusted Life Years; Rimonabant; Treatment Outcome; United States | 2008 |
Rimonabant for the treatment of obesity.
Topics: Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2008 |
Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors.
Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Disease Models, Animal; Endocannabinoids; Energy Metabolism; Humans; Mice; Obesity; Piperidines; Pyrazoles; Rats; Rimonabant; Risk Factors | 2009 |
Current pharmacotherapeutic concepts for the treatment of obesity in adults.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Lipase; Obesity; Orlistat; Piperidines; Prevalence; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Reduction Behavior; Treatment Outcome; Weight Loss | 2009 |
Recent advances in obesity pharmacotherapy.
Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant | 2009 |
Pleiotropic effects of rimonabant: clinical implications.
Topics: Abdominal Fat; Animals; Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors | 2009 |
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disorder; Circadian Rhythm; Cyclobutanes; Depression; Depressive Disorder, Major; Dietary Carbohydrates; Energy Intake; Ghrelin; Humans; Hypothalamo-Hypophyseal System; Insulin Resistance; Leptin; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rimonabant; Seasonal Affective Disorder; Sleep Wake Disorders; Surveys and Questionnaires; Weight Gain; Weight Loss | 2008 |
Effect of antiobesity medications in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabetes Mellitus, Type 2; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome; Weight Loss; Young Adult | 2009 |
The endocannabinoid system: a promising target for the management of type 2 diabetes.
Topics: Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Humans; Hypoglycemic Agents; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Topics: Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fasting; Glucose; Glycated Hemoglobin; Humans; Lipid Metabolism; Metabolic Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2009 |
The endocannabinoid system: potential for reducing cardiometabolic risk.
Topics: Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Mice; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant | 2009 |
Endocannabinoid system and cardio-metabolic risk.
Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
The endocannabinoid system: a new pharmacological target for obesity treatment?
Topics: Animals; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant | 2009 |
The psychiatric side-effects of rimonabant.
Topics: Anxiety Disorders; Appetite Depressants; Cannabinoid Receptor Modulators; Depressive Disorder; Humans; Metabolic Diseases; Obesity; Piperidines; Placebo Effect; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Smoking; Smoking Cessation | 2009 |
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.
Topics: Aged; Amides; Anti-Obesity Agents; Dose-Response Relationship, Drug; Eating; Energy Metabolism; Female; Humans; Male; Obesity; Piperidines; Pyrazoles; Pyridines; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Cannabinoid receptor CB1 antagonists state of the art and challenges.
Topics: Animals; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Energy Metabolism; Humans; Models, Animal; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Rimonabant for the treatment of overweight and obese people.
Topics: Anti-Obesity Agents; Cost-Benefit Analysis; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2009 |
[Adipose tissue inflammation and atherosclerosis].
Topics: Adipokines; Adipose Tissue; Atherosclerosis; Chemotaxis; Cytokines; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Macrophages; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant; Vasoconstrictor Agents | 2009 |
An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Topics: Anti-Obesity Agents; Humans; Molecular Targeted Therapy; Mood Disorders; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant | 2011 |
Pharmacotherapy for obese adolescents.
Topics: Adolescent; Amphetamines; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Central Nervous System Stimulants; Ciliary Neurotrophic Factor; Herbal Medicine; Humans; Hypoglycemic Agents; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant | 2011 |
Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.
Topics: Adiponectin; Adipose Tissue; Animals; Body Mass Index; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Case-Control Studies; Endocannabinoids; Fatty Acids, Nonesterified; Feeding Behavior; Female; Genetic Variation; Humans; Inflammation; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Reference Values; Rimonabant; Risk Factors; Weight Loss | 2011 |
Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Dexfenfluramine; Drug Design; Drug Inverse Agonism; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Receptor Agonists | 2011 |
Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists.
Topics: Animals; Anti-Obesity Agents; Genetic Testing; Humans; Obesity; Piperidines; Polymorphism, Genetic; Precision Medicine; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2011 |
[Pharmacological concepts for the treatment of obesity - a therapeutic meander?].
Topics: Adverse Drug Reaction Reporting Systems; Appetite Depressants; Body Weight; Brain; Combined Modality Therapy; Cyclobutanes; Diet, Reducing; Drug Approval; Drug Combinations; Drug Recalls; Drugs, Investigational; Forecasting; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2011 |
A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity.
Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss | 2012 |
What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.
Topics: Anti-Obesity Agents; Cost-Benefit Analysis; Cyclobutanes; Drug Costs; Exercise; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Primary Health Care; Pyrazoles; Rimonabant; Risk Reduction Behavior; Treatment Outcome | 2012 |
[The pharmacological treatment of obesity: past, present and future].
Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; Benzoxazines; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Fatty Acids; Female; Fenfluramine; Glucagon-Like Peptide 1; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Leptin; Life Style; Liraglutide; Male; Norepinephrine; Obesity; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Pyridines; Receptor, Melanocortin, Type 4; Rimonabant; Satiation; Serotonin; Sodium-Glucose Transport Proteins; Sucrose; Thyroid Hormones | 2012 |
[The potential use of cannabidiol in the therapy of metabolic syndrome].
Topics: Adipocytes; Appetite Depressants; Atherosclerosis; Cannabidiol; Cannabinoid Receptor Antagonists; Disease Progression; Humans; Hyperphagia; Ischemia; Metabolic Syndrome; Obesity; Piperidines; PPAR gamma; Pyrazoles; Rimonabant | 2012 |
CB1 receptor antagonists: new discoveries leading to new perspectives.
Topics: Anti-Obesity Agents; Anxiety Disorders; Depressive Disorder; Humans; Obesity; Piperidines; Precision Medicine; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2012 |
Obesity and diabetes.
Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Sex Characteristics; Sulfonylurea Compounds | 2012 |
Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.
Topics: Animals; Energy Intake; Energy Metabolism; Feeding Behavior; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Drug; Rimonabant | 2003 |
Rimonabant Sanofi-Synthélabo.
Topics: Animals; Anti-Obesity Agents; Antipsychotic Agents; Appetite Depressants; Clinical Trials as Topic; Humans; Obesity; Piperidines; Potassium Channel Blockers; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Structure-Activity Relationship | 2004 |
Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Energy Metabolism; Feeding Behavior; Fructose; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Topiramate | 2004 |
[Endocannabinoid and endocannabinoid receptor antagonists].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Endocannabinoids; Humans; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Tobacco Use Disorder | 2005 |
[Nutrition--obesity].
Topics: Electric Stimulation Therapy; Humans; Nutritional Physiological Phenomena; Nutritional Requirements; Obesity; Piperidines; Pyrazoles; Rimonabant | 2005 |
Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
Topics: Alcoholism; Animals; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
Obesity and cardiovascular physiology: impact of some pharmacological agents.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors | 2005 |
Endocannabinoid control of food intake and energy balance.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Appetite Regulation; Brain; Cannabinoid Receptor Modulators; Endocannabinoids; Energy Metabolism; Humans; Neural Pathways; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Topics: Anti-Obesity Agents; Cannabinoids; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
Topics: Animals; Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Smoking Cessation | 2005 |
[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
Safety of obesity drugs.
Topics: Appetite Depressants; Central Nervous System Stimulants; Drug Approval; Humans; Insurance Coverage; Obesity; Piperidines; Pyrazoles; Rimonabant | 2005 |
[Drug treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diethylpropion; Enzyme Inhibitors; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Weight Loss | 2006 |
Pharmacologic treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fructose; Humans; Isoxazoles; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Selective Serotonin Reuptake Inhibitors; Topiramate; Zonisamide | 2006 |
[New obesity and metabolic syndrome treatment: rimonabant].
Topics: Eating; Humans; Insulin Resistance; Lipid Metabolism; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant | 2006 |
The endocannabinoid system: a new approach to control cardiovascular disease.
Topics: Appetite Regulation; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; History, 20th Century; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2005 |
The metabolic basis of atherogenic dyslipidemia.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Drugs, Investigational; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Pioglitazone; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thiazolidinediones | 2005 |
Pharmacotherapy to reduce visceral fat.
Topics: Anti-Obesity Agents; Coronary Disease; Cyclobutanes; Exercise; Feeding Behavior; Humans; Intra-Abdominal Fat; Lactones; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant | 2005 |
Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Weight Gain | 2006 |
Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Topics: Animals; Disease Management; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Smoking; Smoking Cessation | 2006 |
Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction.
Topics: Cannabinoid Receptor Antagonists; Humans; Models, Biological; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2005 |
[Pharmacotherapy in the treatment of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Cyclobutanes; Enzyme Inhibitors; Exercise; Humans; Lactones; Lipase; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Time Factors; Weight Loss | 2006 |
The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?
Topics: Adipose Tissue; Animals; Appetite Depressants; Appetite Regulation; Brain; Cannabinoid Receptor Modulators; Drug Tolerance; Energy Metabolism; Homeostasis; Humans; Liver; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2006 |
Contribution of CB1 blockade to the management of high-risk abdominal obesity.
Topics: Abdominal Fat; Adiponectin; Animals; Appetite Regulation; Cardiovascular Diseases; Energy Metabolism; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2006 |
Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
Topics: Animals; Atherosclerosis; Blood Glucose; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Lipid Metabolism; Marijuana Abuse; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation | 2006 |
The obesity epidemic and its cardiovascular consequences.
Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Lactones; Life Style; Lipid Metabolism; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Waist-Hip Ratio | 2006 |
Pharmacological treatment of obesity.
Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Energy Metabolism; Homeostasis; Humans; Lactones; Mazindol; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2006 |
Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety; Treatment Outcome | 2006 |
Pharmacologic treatment for obesity. Options for today...and tomorrow.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Therapy, Combination; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2006 |
[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Humans; Metabolic Syndrome; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2006 |
The obesity epidemic: current and future pharmacological treatments.
Topics: Anti-Obesity Agents; Cyclobutanes; Disease Outbreaks; Drug Design; Drugs, Investigational; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant | 2007 |
Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
Topics: Animals; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Smoking Cessation; Substance-Related Disorders | 2006 |
Rimonabant for overweight or obesity.
Topics: Adult; Anti-Obesity Agents; Diet, Reducing; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss | 2006 |
Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy?
Topics: Disease Outbreaks; Glomerulonephritis; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; United Kingdom | 2006 |
Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Endocannabinoids; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Risk Factors; Smoking Cessation | 2006 |
The link between abdominal obesity, metabolic syndrome and cardiovascular disease.
Topics: Cardiovascular Diseases; Fatty Acids, Nonesterified; Humans; Inflammation; Insulin Resistance; Interleukin-6; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Tumor Necrosis Factor-alpha | 2007 |
Pharmacotherapy of obesity.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Design; Energy Metabolism; Homeostasis; Humans; Lactones; Life Style; Models, Biological; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Technology, Pharmaceutical | 2006 |
Metabolic syndrome treatment strategies.
Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Exercise; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Weight Loss | 2006 |
[Selective cannabinoid receptor antagonists].
Topics: Animals; Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Cell Communication; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Signal Transduction | 2006 |
The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
Topics: Cannabinoid Receptor Modulators; Central Nervous System Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Signal Transduction | 2006 |
Drug treatments for obesity: orlistat, sibutramine, and rimonabant.
Topics: Anti-Obesity Agents; Blood Pressure; Cholesterol, HDL; Cyclobutanes; Half-Life; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss | 2007 |
[Pharmacotherapy of obesity].
Topics: Anti-Obesity Agents; Anticonvulsants; Cyclobutanes; Fructose; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Topiramate | 2006 |
Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches.
Topics: Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant | 2007 |
Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity.
Topics: Animals; Humans; Hypothalamo-Hypophyseal System; Intra-Abdominal Fat; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.
Topics: Anti-Obesity Agents; Cannabinoid Receptor Modulators; Drug Interactions; Female; Humans; Male; Obesity; Piperidines; Pyrazoles; Rimonabant | 2007 |
Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
Topics: Anti-Obesity Agents; Antineoplastic Agents; Body Weight; Humans; Neurodegenerative Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Substance-Related Disorders | 2007 |
The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
Topics: Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2007 |
Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
Topics: Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Energy Metabolism; Glucose; Humans; Lipids; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
[New therapeutic aspects for the control of risk factors in obesity].
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant | 2007 |
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss | 2007 |
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Topics: Animals; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Models, Biological; Molecular Structure; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Drug treatment of the overweight patient.
Topics: Animals; Anti-Obesity Agents; Clinical Trials, Phase II as Topic; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome | 2007 |
Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome | 2007 |
Less weight or more hype with rimonabant?
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Drug Costs; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Treatment Outcome; Weight Loss | 2007 |
Cannabinoids and cardiovascular disease: the outlook for clinical treatments.
Topics: Animals; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cannabinoids; Cardiovascular Agents; Cardiovascular Diseases; Cardiovascular System; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Risk Factors; Treatment Outcome | 2007 |
The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Topics: Adipocytes; Adiponectin; Animals; Appetite Regulation; Arachidonic Acids; Cannabinoid Receptor Modulators; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Dronabinol; Eating; Endocannabinoids; Energy Metabolism; Humans; Lipid Metabolism; Obesity; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Cardiovascular disease under the influence of excess visceral fat.
Topics: Adiponectin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Intra-Abdominal Fat; Metabolic Syndrome; Obesity; Piperidines; Prospective Studies; Pyrazoles; Rimonabant; Risk Factors | 2007 |
What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Evaluation; Female; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Treatment Outcome; Waist-Hip Ratio | 2007 |
The endocannabinoid system as a novel approach for managing obesity.
Topics: Abdominal Fat; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Endocannabinoids; Energy Metabolism; Homeostasis; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2007 |
Endocannabinoid system and cardiometabolic risk.
Topics: Abdominal Fat; Adipokines; Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocannabinoids; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss | 2007 |
Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.
Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss | 2007 |
Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dyslipidemias; Exercise; Humans; Insulin Resistance; Life Style; Lipids; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; Treatment Outcome; Weight Loss | 2007 |
Reducing cardiometabolic risk through selective antagonism of CB1 receptors.
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Risk Assessment; Risk Factors | 2007 |
[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Lactones; Neurotransmitter Agents; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome | 2007 |
[Obesity in adults].
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobutanes; Diagnosis, Differential; Enzyme Inhibitors; Humans; Lactones; Male; Middle Aged; Obesity; Obesity, Morbid; Orlistat; Overweight; Piperidines; Prognosis; Pyrazoles; Rimonabant; Time Factors; Weight Loss | 2007 |
Strategies to reduce vascular risk associated with obesity.
Topics: Adiponectin; Anti-Obesity Agents; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Risk Factors | 2007 |
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
Topics: Anti-Obesity Agents; Anxiety Disorders; Depression; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss | 2007 |
The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.
Topics: Brain; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Homeostasis; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors | 2007 |
Cannabinoid-1 receptor antagonists in type-2 diabetes.
Topics: Animals; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Feeding Behavior; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
[Pharmacotherapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome | 2008 |
Role of the endocannabinoid system in metabolic control.
Topics: Anorexia; Cannabinoid Receptor Modulators; Central Nervous System; Endocannabinoids; Ethanolamines; Humans; Obesity; Oleic Acids; Piperidines; Pyrazoles; Rimonabant | 2008 |
Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
Topics: Cardiovascular Diseases; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome | 2007 |
Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
Topics: Cardiovascular Diseases; Drug Tolerance; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome | 2007 |
[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Topics: Cardiovascular Diseases; Depression; Diet, Reducing; Humans; Lipids; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss | 2007 |
Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.
Topics: Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Obesity; Peptides; Piperidines; Pyrazoles; Rimonabant; Venoms | 2007 |
Obesity: a review of pathogenesis and management strategies.
Topics: Anti-Obesity Agents; Bariatric Surgery; Behavior Therapy; Caloric Restriction; Cyclobutanes; Dietary Carbohydrates; Dietary Fats; Exercise; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2008 |
Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about?
Topics: Bariatric Surgery; Cannabinoids; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Life Style; Multicenter Studies as Topic; Obesity; Piperidines; Power, Psychological; Pyrazoles; Rimonabant; Self Concept; Weight Loss | 2008 |
Role of the endocannabinoid system in energy balance regulation and obesity.
Topics: Adipose Tissue; Animals; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Eating; Endocannabinoids; Energy Metabolism; Humans; Hypothalamus; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reward; Rimonabant | 2008 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
Rimonabant: new data and emerging experience.
Topics: Adipose Tissue; Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cholesterol, HDL; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2008 |
Pharmacotherapy for obesity.
Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclobutanes; Exenatide; Gastrointestinal Hormones; Humans; Islet Amyloid Polypeptide; Lactones; Leptin; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Venoms | 2007 |
Endocannabinoids, blood pressure and the human heart.
Topics: Blood Pressure; Blood Vessels; Cannabinoid Receptor Modulators; Cannabinoids; Cardiovascular Physiological Phenomena; Cardiovascular System; Clinical Trials as Topic; Endocannabinoids; Heart; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2008 |
Blood pressure lowering effects of rimonabant in obesity-related hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cannabinoids; Down-Regulation; Humans; Hypertension; Obesity; Piperidines; Pyrazoles; Rimonabant; Sympathetic Nervous System | 2008 |
Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Topics: Animals; Anorexia; Anti-Obesity Agents; Biological Availability; Brain; Cannabinoids; Central Nervous System; Drug Synergism; Eating; Endocannabinoids; Energy Metabolism; Feeding Behavior; Obesity; Oleic Acids; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Triazoles | 2008 |
CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Topics: Algorithms; Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome | 2008 |
The endocannabinoid system and the control of glucose homeostasis.
Topics: Adipose Tissue, White; Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Energy Metabolism; Glucose; Homeostasis; Humans; Liver; Models, Biological; Muscles; Obesity; Pancreas; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Rodentia | 2008 |
The challenge of treating obesity: the endocannabinoid system as a potential target.
Topics: Appetite Regulation; Blood Glucose; Cannabinoid Receptor Modulators; Drug Approval; Endocannabinoids; Energy Metabolism; Humans; Lipid Metabolism; Obesity; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss | 2008 |
Overweight and obesity: key components of cardiometabolic risk.
Topics: Adipocytes; Adipokines; Cardiovascular Diseases; Humans; Inflammation; Life Style; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; United States | 2007 |
Rimonabant. SR 141716, SR 141716a.
Topics: Alzheimer Disease; Clinical Trials as Topic; Cognition Disorders; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2002 |
25 trial(s) available for sr141716 and Obesity
| Article | Year |
|---|---|
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss | 2017 |
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
Topics: Body Mass Index; Cannabinoid Receptor Antagonists; Cytokines; Female; Hepatocyte Growth Factor; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2016 |
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammation; Interleukin-8; Metformin; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Vascular Endothelial Growth Factor A; Weight Loss | 2017 |
Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Topics: Adiponectin; Adiposity; Adult; Anti-Obesity Agents; Apolipoproteins; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Cholesterol, HDL; Double-Blind Method; Dyslipidemias; Female; Humans; Insulin; Intra-Abdominal Fat; Lipoproteins, LDL; Liver; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triglycerides | 2009 |
Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.
Topics: Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2010 |
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant | 2009 |
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2010 |
Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Hormone Antagonists; Humans; Insulin; Middle Aged; Obesity; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Young Adult | 2010 |
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Double-Blind Method; Drug Approval; Female; Gastrointestinal Diseases; Humans; Male; Mental Disorders; Obesity; Piperidines; Pyrazoles; Rimonabant; Suicide | 2010 |
The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment.
Topics: Adult; Apolipoproteins B; Caloric Restriction; Diet, Fat-Restricted; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Retinol-Binding Proteins, Plasma; Rimonabant | 2012 |
Does rimonabant independently affect free fatty acid and glucose metabolism?
Topics: Adult; Aged; Behavior Therapy; Body Composition; Cannabinoid Receptor Antagonists; Diet, Reducing; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucose; Glucose Clamp Technique; Humans; Insulin; Intra-Abdominal Fat; Life Style; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss | 2012 |
Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Cardiovascular Diseases; Counseling; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Outcome Assessment, Health Care; Piperidines; Primary Health Care; Pyrazoles; Quality of Life; Rimonabant; Risk Reduction Behavior; Safety-Based Drug Withdrawals; United Kingdom; Waist Circumference; Young Adult | 2012 |
Fatty acid flux and oxidation are increased by rimonabant in obese women.
Topics: Adiponectin; Aged; Breath Tests; Cannabinoid Receptor Antagonists; Cholesterol; Diet, Reducing; Energy Intake; Energy Metabolism; Fatty Acids; Female; Humans; Insulin Resistance; Leptin; Lipolysis; Lipoproteins, VLDL; Middle Aged; Obesity; Oxidation-Reduction; Palmitic Acids; Piperidines; Pyrazoles; Rimonabant; Triglycerides; United Kingdom; Weight Loss | 2012 |
CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
Topics: Adult; Aged; Cannabinoid Receptor Antagonists; Double-Blind Method; Fatty Liver; Female; Finland; Humans; Liver; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Retrospective Studies; Rimonabant; Treatment Outcome; Weight Loss | 2013 |
Efficacy of rimonabant in obese patients with binge eating disorder.
Topics: Adolescent; Adult; Aged; Binge-Eating Disorder; Cannabinoid Receptor Antagonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2013 |
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Topics: Adiponectin; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Cannabinoid Receptor Antagonists; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Humans; Insulin; Leptin; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Triglycerides; Weight Loss | 2005 |
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Topics: Adult; Aged; Anti-Obesity Agents; Blood Pressure; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Diet, Reducing; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss | 2006 |
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Tolerance; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Overweight; Patient Satisfaction; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome | 2006 |
Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome | 2007 |
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss | 2007 |
Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
Topics: Behavior; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Humans; Lipid Metabolism; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers.
Topics: Appetite Depressants; Cannabinoids; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Obesity; Overweight; Patient Dropouts; Piperidines; Placebos; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss | 2007 |
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Topics: Adult; Blood Pressure; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2008 |
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
Topics: Aged; Atherosclerosis; Coronary Artery Disease; Coronary Vessels; Diet, Reducing; Disease Progression; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Ultrasonography, Interventional | 2008 |
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Triglycerides; Weight Loss | 2008 |
196 other study(ies) available for sr141716 and Obesity
| Article | Year |
|---|---|
Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists.
Topics: Animals; Area Under Curve; Binding, Competitive; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Eating; Humans; Imidazoles; Molecular Structure; Obesity; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2005 |
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
Topics: Animals; Anti-Obesity Agents; Body Weight; Crystallography, X-Ray; Drug Design; Eating; Humans; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Obesity; Piperidines; Pyrazoles; Pyridones; Pyrroles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Weight Gain | 2007 |
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cannabinoids; Cyclic AMP; Eating; Humans; Liver; Microsomes; Obesity; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2006 |
Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Body Weight; Dose-Response Relationship, Drug; Imidazoles; Obesity; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Structure-Activity Relationship | 2007 |
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Benzodioxoles; Body Weight; Crystallography, X-Ray; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypothermia; Ligands; Male; Mice; Microsomes; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2008 |
Aminopyrazine CB1 receptor inverse agonists.
Topics: Animals; Blood Glucose; Combinatorial Chemistry Techniques; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Feeding Behavior; Humans; Microsomes, Liver; Molecular Structure; Obesity; Piperidines; Pyrazines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship | 2008 |
Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Topics: Administration, Oral; Animals; Biological Availability; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Models, Chemical; Models, Molecular; Molecular Structure; Obesity; Oxadiazoles; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Stereoisomerism; Structure-Activity Relationship | 2008 |
Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.
Topics: Animals; Imidazoles; Inhibitory Concentration 50; Obesity; Oxadiazoles; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Thiadiazoles | 2009 |
1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.
Topics: Amides; Benzene; Cannabinoids; Chemistry, Pharmaceutical; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Ligands; Models, Chemical; Obesity; Protein Binding; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Triazoles | 2009 |
Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
Topics: Animals; Anti-Obesity Agents; CHO Cells; Cricetinae; Cricetulus; Inhibitory Concentration 50; Ligands; Obesity; Oxadiazoles; Pyrazoles; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Transfection | 2009 |
Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect.
Topics: Animals; Benzoxazines; Chemistry, Pharmaceutical; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Drug Design; Hair; Inhibitory Concentration 50; Models, Chemical; Morpholines; Naphthalenes; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.
Topics: Animals; Clinical Trials as Topic; Crystallography, X-Ray; Drug Discovery; Humans; Lactams; Obesity; Oxazepines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1 | 2009 |
Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Topics: Animals; Cannabinoids; Cannabis; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mice; Models, Chemical; Molecular Structure; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2009 |
Novel thioamide derivatives as neutral CB1 receptor antagonists.
Topics: Animals; Anti-Obesity Agents; Disease Models, Animal; Mice; Mice, Obese; Obesity; Pyrazines; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Thioamides | 2010 |
Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
Topics: Amides; Animals; Anti-Obesity Agents; Blood-Brain Barrier; Body Weight; Drug Inverse Agonism; Mice; Obesity; Piperidines; Protein Binding; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship | 2010 |
Diaryl piperidines as CB1 receptor antagonists.
Topics: Animals; Diet; Eating; Mice; Mice, Obese; Obesity; Piperidines; Protein Binding; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2010 |
Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Humans; Male; Mice; Mice, Inbred C57BL; Obesity; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Thiadiazoles | 2010 |
Identification and hit-to-lead optimization of a novel class of CB1 antagonists.
Topics: Animals; Benzimidazoles; Humans; Hypothermia; Indoles; Male; Mice; Microsomes, Liver; Obesity; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Solubility; Structure-Activity Relationship | 2010 |
Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.
Topics: Animals; Anti-Obesity Agents; Brain; Humans; Obesity; Radiography; Radioligand Assay; Rats; Receptor, Cannabinoid, CB1 | 2011 |
Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor.
Topics: Animals; Anti-Obesity Agents; Dogs; Halogenation; Humans; Macaca fascicularis; Male; Mice; Obesity; Pyrimidines; Rats; Receptors, Somatostatin; Structure-Activity Relationship | 2016 |
Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB
Topics: Animals; Anti-Obesity Agents; Body Weight; Brain; Cannabinoid Receptor Antagonists; Diet, High-Fat; Drug Inverse Agonism; Hydrophobic and Hydrophilic Interactions; Male; Mice, Inbred C57BL; Molecular Structure; Obesity; Pyrazoles; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship | 2022 |
Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model.
Topics: Animals; Body Weight; Diet; Drug Inverse Agonism; Incretins; Liraglutide; Mice; Obesity; Receptors, Cannabinoid; Rimonabant; Weight Loss | 2023 |
Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return?
Topics: Adipose Tissue; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Endocannabinoids; Humans; Obesity; Pandemics; Pneumonia, Viral; Prevalence; Respiration, Artificial; Rimonabant; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
Topics: Animals; Blood Glucose; Body Weight; Calcium Channels; Calcium Channels, L-Type; Cannabinoid Receptor Antagonists; Diet, High-Fat; Glucose Intolerance; Insulin Resistance; Male; Mice, Inbred C57BL; Models, Animal; Muscle, Skeletal; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2017 |
Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity.
Topics: Adipose Tissue; Animals; Cannabinoid Receptor Antagonists; Cell Movement; Cytokines; Gastrointestinal Microbiome; Inflammation; Macrophages; Male; Mice; Obesity; Receptor, Cannabinoid, CB1; Rimonabant | 2017 |
Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity.
Topics: Adipose Tissue; Animals; Brain; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Experimental; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Obese; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; Rimonabant | 2018 |
Orosensory Detection of Dietary Fatty Acids Is Altered in CB₁R
Topics: Animals; Calcium Signaling; Cannabinoid Receptor Antagonists; CD36 Antigens; Dietary Fats; Fatty Acids; Food Preferences; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Linoleic Acid; Male; Mice, Knockout; Obesity; Proglucagon; Rapeseed Oil; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Rimonabant; RNA, Messenger; Taste; Taste Buds; Taste Perception | 2018 |
CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes.
Topics: Adenylate Kinase; Animals; Diabetes Mellitus, Experimental; Fatty Liver; Inflammation; Liver; NF-E2-Related Factor 2; Obesity; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant; Severity of Illness Index; Signal Transduction | 2018 |
Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity.
Topics: Adipose Tissue; Administration, Oral; Animals; Body Weight; Cannabinoid Receptor Antagonists; Carnitine O-Palmitoyltransferase; Cholesterol; Diet, High-Fat; Leptin; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myocardium; Obesity; PPAR alpha; Receptor, Cannabinoid, CB1; Rimonabant | 2018 |
A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
Topics: 3T3 Cells; Adipose Tissue; Animals; CHO Cells; Cricetulus; Cytokines; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Humans; Hypoglycemic Agents; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; RAW 264.7 Cells; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Weight Loss | 2019 |
Role of microRNA in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity.
Topics: Adipose Tissue; Animals; Chemotaxis; Dietary Fats; Gene Expression Regulation; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Macrophages; Male; Mice; MicroRNAs; Obesity; Receptor, Cannabinoid, CB1; Rimonabant; STAT6 Transcription Factor | 2019 |
Developmental role for endocannabinoid signaling in regulating glucose metabolism and growth.
Topics: Animals; Cannabinoid Receptor Antagonists; Endocannabinoids; Glucose; Insulin; Insulin-Like Growth Factor I; Leptin; Liver; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Leptin; Rimonabant; Signal Transduction | 2013 |
Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
Topics: Adipose Tissue; Animals; Animals, Newborn; Cannabinoid Receptor Antagonists; Fatty Liver; Female; Glucose Intolerance; Hyperlipidemias; Insulin Resistance; Liver; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Insulin; Rimonabant; Sodium Glutamate | 2013 |
Synergic insulin sensitizing effect of rimonabant and BGP-15 in Zucker-obese rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Disease Models, Animal; Drug Synergism; Glucose; Glucose Clamp Technique; Hyperinsulinism; Insulin; Insulin Resistance; Male; Obesity; Oximes; Piperidines; Pyrazoles; Rats; Rats, Zucker; Rimonabant | 2013 |
NESS06SM reduces body weight with an improved profile relative to SR141716A.
Topics: Animals; Anti-Obesity Agents; Benzoxepins; Body Weight; Cannabinoid Receptor Antagonists; Diet, High-Fat; Fatty Acid Synthases; Glucokinase; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Pyruvate Kinase; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Symporters | 2013 |
Anti-obesity effect of Gymnema sylvestre extract on high fat diet-induced obesity in Wistar rats.
Topics: Animals; Anti-Obesity Agents; Antioxidants; Diet, High-Fat; Disease Models, Animal; Gymnema sylvestre; Male; Medicine, Ayurvedic; Obesity; Piperidines; Plant Extracts; Pyrazoles; Rats; Rats, Wistar; Rimonabant | 2013 |
Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.
Topics: Adiposity; Animals; Basal Metabolism; Bile Acids and Salts; Body Weight; Caloric Restriction; Diet; Drug Therapy, Combination; Fatty Acids; Fatty Liver; Feeding Behavior; Fibroblast Growth Factors; Gene Expression Regulation; Hepatocytes; Insulin; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oligonucleotides, Antisense; Oxidation-Reduction; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Fibroblast Growth Factor, Type 4; Rimonabant | 2013 |
Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Topics: Adiponectin; Adiposity; Animals; Body Weight; Cannabinoid Receptor Antagonists; Diet, High-Fat; Energy Intake; Fatty Liver; Leptin; Lipid Metabolism; Lipids; Liver; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2014 |
Rimonabant's reductive effects on high densities of food reinforcement, but not palatability, in lean and obese Zucker rats.
Topics: Animals; Behavior, Animal; Choice Behavior; Eating; Feeding Behavior; Food Preferences; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Reinforcement Schedule; Reinforcement, Psychology; Rimonabant | 2014 |
A stepwise likelihood ratio test procedure for rare variant selection in case-control studies.
Topics: Aged; Amidohydrolases; Case-Control Studies; Computer Simulation; Female; Gene Frequency; Genetic Variation; Humans; Likelihood Functions; Male; Mathematical Computing; Middle Aged; Models, Genetic; Monoacylglycerol Lipases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Statistical Distributions | 2014 |
Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity.
Topics: 3T3-L1 Cells; Absorptiometry, Photon; Adipose Tissue, Brown; Animals; Base Sequence; DNA Primers; Dyslipidemias; Mice; Mice, Transgenic; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant | 2014 |
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms | 2014 |
A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eating; Energy Metabolism; Fatty Liver; Ion Channels; Lipolysis; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thermogenesis; Thiophenes; Uncoupling Protein 1; Weight Loss | 2015 |
Combination cannabinoid and opioid receptor antagonists improves metabolic outcomes in obese mice.
Topics: Animals; Body Composition; Cannabinoid Receptor Antagonists; Drug Therapy, Combination; Glucose; Insulin; Male; Mice; Mice, Obese; Naloxone; Narcotic Antagonists; Obesity; Piperidines; Pyrazoles; Rimonabant; Thermogenesis; Treatment Outcome | 2015 |
Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.
Topics: Animals; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Down-Regulation; Drug Inverse Agonism; Eating; Endocannabinoids; Endoplasmic Reticulum Stress; Humans; Inflammation; Insulin Resistance; Mitochondria; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction | 2016 |
[The endocannabinoid system].
Topics: Blood Glucose; Body Weight; Cannabinoid Receptor Modulators; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Endocannabinoids; Energy Metabolism; Europe; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2008 |
Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.
Topics: Animals; Anti-Obesity Agents; CHO Cells; Cricetinae; Cricetulus; Humans; Imidazoles; Isomerism; Models, Chemical; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Solubility; Structure-Activity Relationship; Thiazoles; Triazoles; Water | 2008 |
Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions.
Topics: Age Factors; Animals; Autoradiography; Body Weight; Cannabinoid Receptor Modulators; Eating; Food Deprivation; Hyperphagia; Leptin; Limbic System; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Receptors, Leptin; Rimonabant; Tritium; Up-Regulation | 2008 |
[Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2008 |
The element of surprise.
Topics: Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Delusions; Drug Administration Schedule; Humans; Lipogenesis; Mice; Mice, Knockout; Models, Biological; Nerve Endings; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Schizophrenia; Waist-Hip Ratio; Weight Loss | 2008 |
Rimonabant and progression of atherosclerosis in obese persons.
Topics: Anti-Obesity Agents; Atherosclerosis; Coronary Artery Disease; Ethics, Research; Humans; Obesity; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Research Design; Rimonabant; Ultrasonography | 2008 |
Depression and weight loss: opposite outcome for surgery and rimonabant?
Topics: Anti-Obesity Agents; Depression; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss | 2008 |
Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Humans; Intra-Abdominal Fat; Obesity; Patient Selection; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Treatment Outcome | 2008 |
Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Topics: Acetyl-CoA Carboxylase; Adipose Tissue; Animals; Body Weight; Chromatography, Liquid; Dietary Fats; Eating; Fatty Acid Synthases; Glucose Clamp Technique; Lipid Metabolism; Lipoprotein Lipase; Male; Mass Spectrometry; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; Triglycerides | 2008 |
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Meta-Analysis as Topic; Obesity; Piperidines; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Sex Factors | 2008 |
[Pharmacological therapy of obesity].
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Economics, Pharmaceutical; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Practice Guidelines as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Time Factors; Weight Loss | 2008 |
Is rimonabant efficacious and safe in the treatment of obesity?
Topics: Controlled Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Obesity; Piperidines; Placebos; Pyrazoles; Rimonabant; Treatment Outcome | 2008 |
Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice.
Topics: Abdominal Fat; Adipocytes; Animals; Blood Glucose; Body Weight; Cannabinoid Receptor Antagonists; Dietary Fats; Extracellular Matrix; Gene Expression Regulation; Insulin; Leptin; Lipoproteins, VLDL; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Rimonabant; Subcutaneous Fat; Transcription, Genetic | 2008 |
End of the line for cannabinoid receptor 1 as an anti-obesity target?
Topics: Anti-Obesity Agents; Cannabinoid Receptor Modulators; Dexfenfluramine; Eating; Humans; Life Style; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Risk Assessment; Risk Factors | 2008 |
The endocannabinoid system as a target for obesity treatment.
Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabinoids; Humans; Lactones; Life Style; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Pyridines; Rimonabant; Risk | 2008 |
Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
Topics: Animals; Atherosclerosis; Cannabinoids; Clinical Trials as Topic; Heart Diseases; Humans; Metabolic Diseases; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, LDL; Rimonabant; Weight Gain | 2009 |
Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Atherectomy, Coronary; Cannabinoid Receptor Modulators; Cell Differentiation; Cell Line; Cells, Cultured; Coronary Artery Disease; Cytokines; Endocannabinoids; Humans; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Monocytes; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Vasculitis | 2009 |
Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
Topics: Adiponectin; Animals; Anti-Obesity Agents; Dietary Fats; Disease Models, Animal; Eating; Glucose; Glucose Tolerance Test; Hyperinsulinism; Insulin; Insulin Resistance; Intra-Abdominal Fat; Lipids; Liver; Male; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Rimonabant; Subcutaneous Fat; Weight Loss | 2009 |
[Nutrition-obesity. Rimonabant and cardiovascular risk factors].
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors | 2009 |
Cannabinoid receptor-1 blockade attenuates acute pancreatitis in obesity by an adiponectin mediated mechanism.
Topics: Adiponectin; Animals; Chemokine CCL2; Interleukin-6; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pancreatitis; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2009 |
ADAGIO-Lipids gives promises but faces the setbacks.
Topics: Adiponectin; Adiposity; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Humans; Insulin; Intra-Abdominal Fat; Lipids; Liver; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Treatment Outcome | 2009 |
Impairments in endocannabinoid signaling and depressive illness.
Topics: Affect; Anti-Obesity Agents; Antidepressive Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Depression; Depressive Disorder; Endocannabinoids; Humans; Ligands; Obesity; Piperidines; Pyrazoles; Research; Rimonabant; Signal Transduction; Tobacco Use Disorder | 2009 |
Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
Topics: Animals; Body Composition; Cannabinoid Receptor Modulators; Eating; Glucose; Glucose Tolerance Test; Insulin; Lipid Metabolism; Lipids; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship.
Topics: Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Conflict of Interest; Disclosure; Drug Industry; Endocannabinoids; Humans; MEDLINE; Obesity; Piperidines; Pyrazoles; Research Support as Topic; Review Literature as Topic; Rimonabant; Scientific Misconduct | 2009 |
Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.
Topics: Animals; Body Weight; Dietary Fats; Dogs; Eating; Energy Metabolism; Intra-Abdominal Fat; Magnetic Resonance Imaging; Male; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Subcutaneous Fat, Abdominal | 2009 |
[2008: the end of rimonabant's story].
Topics: Anti-Obesity Agents; Dronabinol; Drug Approval; France; History, 21st Century; Humans; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant | 2009 |
Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats.
Topics: Acetylcholine; Animals; Aorta; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Rate; Indomethacin; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Obesity; Phenylephrine; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Vasoconstriction; Vasodilation | 2009 |
End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.
Topics: Anti-Obesity Agents; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
Topics: Body Mass Index; Comorbidity; Cost-Benefit Analysis; Decision Making, Organizational; Drug Prescriptions; Dyslipidemias; Economics, Pharmaceutical; Humans; Insurance, Pharmaceutical Services; Obesity; Piperidines; Pyrazoles; Reimbursement Mechanisms; Rimonabant; State Medicine; Sweden | 2010 |
The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets.
Topics: Animals; Glucose; Insulin; Insulin Secretion; Islets of Langerhans; Male; Obesity; Palmitates; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Secretory Rate | 2009 |
Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Comorbidity; Eating; Epilepsies, Partial; Epilepsy, Generalized; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant | 2009 |
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Topics: Analgesics; Arrestins; beta-Arrestins; Cannabinoid Receptor Agonists; Cannabinoids; Cell Line; Cyclohexanols; Humans; Ligands; Lysophospholipids; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Obesity; Phosphorylation; Piperidines; Protein Kinase C; Protein Kinase C beta; Pyrazoles; Receptors, Cannabinoid; Receptors, G-Protein-Coupled; Rimonabant | 2009 |
Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition.
Topics: Animals; Body Weight; Cannabinoids; Dietary Fats; Energy Metabolism; Fatty Acids; Fish Oils; Gene Expression Regulation, Enzymologic; Male; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
CB1 antagonists for obesity--what lessons have we learned from rimonabant?
Topics: Anti-Obesity Agents; Cannabinoid Receptor Modulators; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.
Topics: Adipocytes, White; Adipose Tissue, Brown; Animals; Cannabinoid Receptor Antagonists; Cell Transdifferentiation; Gene Expression; Mice; Obesity; Phenotype; Piperidines; PPAR gamma; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant | 2010 |
Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Topics: Adipokines; Adiponectin; Adipose Tissue; Adipose Tissue, White; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Down-Regulation; Female; Gene Expression; Glucose Intolerance; Glucose Tolerance Test; Insulin; Insulin Resistance; Leptin; Mice; Mice, Knockout; Models, Animal; Nicotinamide Phosphoribosyltransferase; Obesity; Organ Size; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Retinol-Binding Proteins, Plasma; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA, Messenger; Tumor Necrosis Factor-alpha | 2009 |
Pharmacotherapy for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Body Weight; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Time Factors | 2009 |
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Topics: Amides; Analysis of Variance; Animals; Autoradiography; Benzoxazines; Body Weight; Brain; Cyclohexanols; Diet Fads; Disease Models, Animal; Eating; Female; Guanosine 5'-O-(3-Thiotriphosphate); International Cooperation; Morpholines; Naphthalenes; Obesity; Piperidines; Protein Binding; Pyrazoles; Pyridines; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Sulfur Isotopes; Time Factors; Tomography Scanners, X-Ray Computed; Tritium; Whole Body Imaging | 2010 |
FAAH deficiency promotes energy storage and enhances the motivation for food.
Topics: Adiposity; Amidohydrolases; Animals; Arachidonic Acids; Body Weight; Cannabinoid Receptor Modulators; Conditioning, Operant; Darkness; Dietary Fats; Eating; Endocannabinoids; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motivation; Obesity; Oleic Acids; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rimonabant; Triglycerides | 2010 |
Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
Topics: Adiposity; Animals; Benzoxazines; Brain; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Feeding Behavior; Hypothermia; Male; Mice; Mice, Inbred C57BL; Morpholines; Naphthalenes; Obesity; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Sterol Regulatory Element Binding Protein 1; Tissue Distribution | 2010 |
Psychosis following anti-obesity treatment with rimonabant.
Topics: Adult; Anti-Obesity Agents; Chronic Disease; Female; Humans; Obesity; Piperidines; Pyrazoles; Recurrence; Rimonabant; Schizophrenia, Paranoid | 2008 |
CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
Topics: Adiponectin; Adipose Tissue; Animal Feed; Animals; Apolipoproteins A; Apolipoproteins B; Body Weight; Cannabinoid Receptor Antagonists; Diet; Fatty Liver; Gene Expression Regulation; Liver; Mice; Mice, Obese; Obesity; Organ Size; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sucrose | 2010 |
Rimonabant during early pregnancy.
Topics: Adult; Anti-Obesity Agents; Female; Humans; Obesity; Piperidines; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pyrazoles; Rimonabant | 2010 |
TrkB agonist antibody dose-dependently raises blood pressure in mice with diet-induced obesity.
Topics: Animals; Anti-Obesity Agents; Antibodies, Monoclonal; Blood Pressure; Body Weight; Brain-Derived Neurotrophic Factor; Diet; Dietary Fats; Hypertension; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, trkB; Rimonabant; Telemetry; Weight Loss | 2010 |
Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Obesity Agents; Blood Glucose; Cell Line; Culture Media, Conditioned; Diabetes Mellitus, Experimental; Dietary Fats; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Interleukin-10; Lipopolysaccharides; Macrophages; Male; Mice; Obesity; Phosphorylation; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Tumor Necrosis Factor-alpha | 2010 |
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
Topics: Adipose Tissue; Animals; Appetite; Biogenic Monoamines; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cyclobutanes; Diet; Eating; Glucose Tolerance Test; Lipids; Male; Neurotransmitter Uptake Inhibitors; Obesity; Piperidines; Pyrazoles; Rats; Rimonabant; Time Factors; Weight Loss | 2010 |
How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.
Topics: Anti-Obesity Agents; Drug Design; Drug Inverse Agonism; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction | 2010 |
Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
Topics: Animals; Body Composition; Eating; Energy Metabolism; Homeostasis; Mice; Neuropeptide Y; Obesity; Oxidation-Reduction; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Neuropeptide Y; Rimonabant | 2010 |
Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
Topics: Animals; Appetite Regulation; Body Weight; Cannabinoid Receptor Modulators; Diabetes Mellitus, Type 2; Endocannabinoids; Humans; Mice; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Topics: Animals; Insulin Resistance; Leptin; Liver; Male; Mice; Mice, Inbred C57BL; Morpholines; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Triglycerides | 2010 |
The endocannabinoid system links gut microbiota to adipogenesis.
Topics: Adipogenesis; Adipose Tissue; Animals; Arachidonic Acids; Bacterial Translocation; Caco-2 Cells; Cannabinoid Receptor Modulators; Disease Models, Animal; Dronabinol; Endocannabinoids; Glycerides; Humans; Intestinal Mucosa; Intestines; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Obesity; Permeability; Piperidines; Polyunsaturated Alkamides; Prebiotics; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger | 2010 |
Rimonabant: obituary for a wonder drug.
Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2010 |
Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-oxygenase-derived products on arteries from obese Zucker rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Body Weight; Endothelium, Vascular; Nitric Oxide Synthase Type II; Nitrobenzenes; Obesity; Phenylephrine; Piperidines; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Sulfonamides; Tumor Necrosis Factor-alpha; Vasodilation; Vasodilator Agents | 2010 |
Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Chemokine CCL2; Diet; Dietary Fats; Disease Models, Animal; Energy Intake; Inflammation; Liver; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Gain; Weight Loss | 2011 |
Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
Topics: Analysis of Variance; Animals; Body Weight; Diet; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Leptin; Mice; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Signal Transduction | 2011 |
Feeding disorders and obesity.
Topics: Amides; Animals; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Eating; Energy Metabolism; Feeding and Eating Disorders; Humans; Islets of Langerhans; Liver; Muscle, Skeletal; Obesity; Piperidines; Pyrazoles; Pyridines; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant.
Topics: Humans; Hypoglycemic Agents; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2011 |
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Evidence-Based Medicine; Humans; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Treatment Outcome; Weight Loss | 2011 |
Feedback and lessons from the prescription of rimonabant, a drug to be used under strict guidelines, in southeastern France, March 2007 through June 2008.
Topics: Adult; Antidepressive Agents; Body Mass Index; Depressive Disorder; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Prescriptions; Feedback; Female; France; Humans; Insurance, Health, Reimbursement; Logistic Models; Male; Middle Aged; Obesity; Piperidines; Practice Guidelines as Topic; Pyrazoles; Retrospective Studies; Rimonabant | 2011 |
Retinol-binding protein 4 : a possible role in cardiovascular complications.
Topics: 3T3-L1 Cells; Adipokines; Animals; Apolipoprotein E3; Atherosclerosis; Base Sequence; Cardiovascular Diseases; Cholesterol; DNA Primers; Female; Gene Expression Regulation; Hypercholesterolemia; Inflammation; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Real-Time Polymerase Chain Reaction; Retinol-Binding Proteins, Plasma; Rimonabant | 2011 |
The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Topics: Adiponectin; Adiposity; Animals; Anti-Obesity Agents; Biomarkers; Body Weight; Central Nervous System; Cholesterol; Diet, High-Fat; Energy Intake; Gastrointestinal Transit; Hypothermia; Insulin; Leptin; Mice; Mice, Knockout; Mice, Transgenic; MicroRNAs; Mutation; Obesity; Peripheral Nervous System; Phenotype; Piperidines; Promoter Regions, Genetic; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Triglycerides | 2011 |
Large size cells in the visceral adipose depot predict insulin resistance in the canine model.
Topics: Adipocytes; Adiposity; Animals; Cell Size; Diet, High-Fat; Dogs; Insulin Resistance; Intra-Abdominal Fat; Linear Models; Male; Models, Animal; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2011 |
Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Inverse Agonism; Extinction, Psychological; Macaca fascicularis; Male; Mice; Mice, Inbred C57BL; Motor Activity; Obesity; Piperidines; Pyrazoles; Pyrimidinones; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Sleep, REM; Tissue Distribution | 2011 |
Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Carbohydrate Metabolism; Cholesterol; Disease Models, Animal; Dyslipidemias; Fatty Liver; Gene Expression Regulation; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; Oxygen Consumption; Piperidines; Protein Kinases; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Tissue Culture Techniques | 2012 |
Rimonabant reduces the essential value of food in the genetically obese Zucker rat: an exponential demand analysis.
Topics: Analysis of Variance; Animals; Cannabinoids; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Eating; Feeding Behavior; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Reinforcement Schedule; Rimonabant | 2012 |
Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice.
Topics: Adipose Tissue; Administration, Oral; Animals; Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Eating; Energy Intake; Energy Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2012 |
CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Topics: Abdominal Fat; Adiponectin; Animals; Blood Glucose; Body Composition; Cannabinoid Receptor Antagonists; Dietary Fats; Disease Models, Animal; Dogs; Energy Intake; Fatty Acids, Nonesterified; Glucose Clamp Technique; Insulin; Insulin Resistance; Liver; Male; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2012 |
Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
Topics: Adipose Tissue, Brown; Adipose Tissue, White; Affect; Animals; Anti-Obesity Agents; Body Weight; Drug Therapy, Combination; Hypothalamic Hormones; Lipolysis; Male; Melanins; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Physical Conditioning, Animal; Piperidines; Pituitary Hormones; Pyrazoles; Rimonabant; Thermogenesis; Weight Loss | 2013 |
Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats.
Topics: Adiposity; Animals; Anti-Obesity Agents; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Lactones; Male; Obesity; Orlistat; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Weight Gain | 2012 |
Food and Drug Administration's Obesity Drug Guidance Document: a short history.
Topics: Adolescent; Adult; Advisory Committees; Aged; Anti-Obesity Agents; Bariatric Medicine; Body Mass Index; Child; Congresses as Topic; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Approval; Drug Discovery; Female; History, 20th Century; History, 21st Century; Humans; Male; Middle Aged; Multicenter Studies as Topic; Obesity; Outcome Assessment, Health Care; Piperidines; Practice Guidelines as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Reference Standards; Rimonabant; Safety-Based Drug Withdrawals; United States; United States Food and Drug Administration | 2012 |
Fasting induces CART down-regulation in the zebrafish nervous system in a cannabinoid receptor 1-dependent manner.
Topics: Animals; Appetite Regulation; Brain; Cannabinoid Receptor Agonists; Down-Regulation; Food Deprivation; Gene Expression Regulation, Developmental; Gene Knockdown Techniques; Larva; Molecular Sequence Data; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Yolk Sac; Zebrafish | 2012 |
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Topics: Analysis of Variance; Animals; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Body Weight; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Cholesterol; Dietary Fats; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypothalamus; Indazoles; Intra-Abdominal Fat; Liver; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Plasma Membrane Transport Proteins; Thiophenes; Transaminases; Triglycerides | 2012 |
Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.
Topics: Adiposity; AMP-Activated Protein Kinases; Animals; Diet; Dyslipidemias; Energy Metabolism; Enzyme Activation; Gene Silencing; Gene Targeting; Glucose Intolerance; Hyperinsulinism; Hyperphagia; Hypothalamus; Mice; Mice, Inbred C57BL; Obesity; Phosphorylation; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Rimonabant; Weight Loss | 2012 |
Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant.
Topics: Adult; Aged; Blood Glucose; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Diet; Dietary Carbohydrates; Dietary Fats; Energy Intake; Female; Humans; Male; Micronutrients; Middle Aged; Obesity; Piperidines; Pyrazoles; Regression Analysis; Rimonabant; Weight Loss | 2012 |
Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity.
Topics: Abdominal Fat; Adipocytes; Adipokines; Adiponectin; Adipose Tissue; Adult; Blotting, Western; Cannabinoid Receptor Antagonists; Cells, Cultured; Chemokine CCL4; Down-Regulation; Female; Gene Expression; Gene Expression Regulation; Humans; Interleukin-1beta; Interleukin-7; Male; Obesity; Omentum; p38 Mitogen-Activated Protein Kinases; Piperidines; Pyrazoles; Real-Time Polymerase Chain Reaction; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Up-Regulation | 2013 |
Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats.
Topics: Animals; Chemokine CCL2; Lipids; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha | 2012 |
Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
Topics: Animals; Appetite Depressants; Blood-Brain Barrier; Body Temperature; Cannabinoid Receptor Antagonists; Drug Evaluation, Preclinical; Eating; Gastrointestinal Transit; Male; Mice; Molecular Structure; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Vas Deferens | 2012 |
Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring study.
Topics: Adult; Body Mass Index; Cannabinoid Receptor Antagonists; Cohort Studies; Drug Monitoring; Drug Prescriptions; Female; Humans; Male; Mental Disorders; Middle Aged; Obesity; Patient Compliance; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Substance Withdrawal Syndrome; Time Factors | 2012 |
Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.
Topics: Amygdala; Animals; Anxiety; Dopaminergic Neurons; Eating; GABAergic Neurons; Humans; Male; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Ventral Tegmental Area; Weight Gain | 2013 |
Impulsive-choice patterns for food in genetically lean and obese Zucker rats.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Antagonists; Choice Behavior; Conditioning, Operant; Feeding Behavior; Food Preferences; Impulsive Behavior; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Rimonabant; Sucrose | 2013 |
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.
Topics: Animals; Binding Sites; Body Weight; Diet; Dietary Fats; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Insulin; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Time Factors | 2003 |
Endogenous cannabinoids: a new target in the treatment of obesity.
Topics: Animals; Appetite; Cannabinoids; Feeding Behavior; Mice; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Rimonabant | 2003 |
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Body Weight; Cannabinoids; Cells, Cultured; Disease Models, Animal; Gene Expression; Hyperinsulinism; Intercellular Signaling Peptides and Proteins; Male; Mice; Obesity; Piperidines; Protein Biosynthesis; Proteins; Pyrazoles; Rats; Rats, Zucker; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; RNA, Messenger | 2003 |
Experimental drugs take aim at obesity.
Topics: Animals; Anti-Obesity Agents; Ciliary Neurotrophic Factor; Cyclobutanes; Drug Evaluation; Drugs, Investigational; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Recombinant Proteins; Rimonabant; United States; United States Food and Drug Administration | 2003 |
Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.
Topics: Animals; Carrier Proteins; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Neuropeptides; Obesity; Orexin Receptors; Orexins; Pertussis Toxin; Piperidines; Protein Binding; Pyrazoles; Receptor Cross-Talk; Receptors, Cannabinoid; Receptors, Drug; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Receptors, Neuropeptide Y; Rimonabant; Transfection | 2003 |
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
Topics: Animals; Body Weight; Diet; Dietary Fats; Eating; Energy Intake; Energy Metabolism; Insulin; Insulin Resistance; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Leptin; Recombinant Proteins; Rimonabant; Thinness | 2004 |
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.
Topics: Appetite Depressants; Cannabinoid Receptor Antagonists; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant | 2004 |
[Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction].
Topics: Appetite; Body Weight; Brain; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome | 2004 |
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice.
Topics: Animals; Blood Glucose; Body Weight; Eating; Energy Metabolism; Female; Mice; Mice, Obese; Muscle, Skeletal; Obesity; Oxygen Consumption; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thermogenesis; Tissue Culture Techniques | 2005 |
The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
Topics: Adiponectin; Animals; Anti-Obesity Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Insulin; Intercellular Signaling Peptides and Proteins; Leptin; Lipids; Male; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Rimonabant | 2005 |
The weight debate, continued.
Topics: Body Mass Index; Controlled Clinical Trials as Topic; Cultural Characteristics; Humans; Obesity; Piperidines; Placebos; Pyrazoles; Rimonabant; United States | 2004 |
Cannabis antagonists: a new era of social psychopharmacology?
Topics: Anti-Obesity Agents; Cannabinoids; Cannabis; Humans; Marijuana Abuse; Obesity; Piperidines; Psychopharmacology; Pyrazoles; Rimonabant | 2005 |
Another pill for weight reduction.
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2005 |
New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2005 |
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesity; Piperidines; Platelet Aggregation Inhibitors; Pyrazoles; Rimonabant; Stroke; Ticlopidine | 2005 |
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
Topics: Adipocytes; Adiponectin; Animals; Cytoskeleton; Dietary Fats; Energy Intake; Energy Metabolism; Gene Expression Profiling; Glucose; Lipolysis; Male; Mice; Mice, Inbred C57BL; Obesity; Phenotype; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thermogenesis | 2005 |
New options for drug treatment of obesity in patients with Type 2 diabetes.
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant | 2005 |
FDA standards--good enough for government work?
Topics: Cannabinoids; Dexfenfluramine; Drug Approval; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Sleep Initiation and Maintenance Disorders; United States; United States Food and Drug Administration | 2005 |
Appetite downer awaits approval.
Topics: Appetite; Appetite Depressants; Clinical Trials as Topic; Diabetes Mellitus; Drug Approval; Drug Industry; Europe; France; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss | 2005 |
Pharmacotherapy for obesity--promise and uncertainty.
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Cyclobutanes; Dyslipidemias; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2005 |
New drugs for prevention, relief. How you might benefit if 3 medications win FDA approval.
Topics: Acetanilides; Angina Pectoris; Benzazepines; Heart Failure; Humans; Obesity; Piperazines; Piperidines; Pyrazoles; Ranolazine; Rimonabant; Tolvaptan | 2005 |
Tackling obesity and nicotine dependence.
Topics: Animals; Humans; Immunotherapy; Indoles; Obesity; Piperidines; Pyrazoles; Rimonabant; Serotonin Antagonists; Smoking Cessation; Tobacco Use Disorder | 2005 |
Rimonabant adds appetizing choice to slim obesity market.
Topics: Appetite Depressants; Drug Evaluation; Drug Industry; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2006 |
Drug development. Drugs inspired by a drug.
Topics: Animals; Anti-Obesity Agents; Anxiety; Arachidonic Acids; Blood Pressure; Brain; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Endocannabinoids; Humans; Inflammation; Neurons; Obesity; Osteoporosis; Pain; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Smoking Cessation | 2006 |
[Reducing obesity].
Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Child; Cyclobutanes; Female; Humans; Life Style; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Surveys and Questionnaires; Weight Loss | 2006 |
Metabolic risk factors, drugs, and obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Dyslipidemias; Glucose Intolerance; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2006 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones | 2006 |
Update on rimonabant--a selective cannabinoid CB1 antagonist.
Topics: Cardiovascular Diseases; Dyslipidemias; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2006 |
The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
Topics: Adiponectin; Animals; Body Weight; Dietary Fats; Eating; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2006 |
Effect of rimonabant on weight and cardiometabolic risk factors.
Topics: Anti-Obesity Agents; Anxiety; Depression; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors | 2006 |
Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
Topics: Anti-Obesity Agents; Humans; Life Style; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk; Weight Loss | 2006 |
[Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke].
Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Time Factors; Triglycerides; Weight Loss | 2006 |
Obesity drug development - CBI's 2nd Annual Summit.
Topics: Adipocytes; Animals; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Disease Models, Animal; Drug Design; Estrone; Fatty Acids; Humans; Obesity; Oleic Acids; Oxidation-Reduction; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2006 |
Better strategies sought against obesity.
Topics: Adiposity; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Diet Therapy; Humans; Insulin; Insulin Detemir; Insulin, Long-Acting; Leptin; Obesity; Piperidines; Pyrazoles; Rimonabant | 2006 |
Does rimonabant pull its weight for type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2006 |
Rimonabant.
Topics: Adult; Animals; Anti-Obesity Agents; Blood Glucose; Clinical Trials as Topic; Diet, Reducing; Drug Approval; Europe; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2006 |
[Acomplia, an essential medication or a "comfort" product?].
Topics: Germany; Humans; Insurance, Pharmaceutical Services; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2006 |
Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats.
Topics: Animals; Cannabinoid Receptor Antagonists; Energy Intake; Fasting; Feeding Behavior; Hypothalamo-Hypophyseal System; Male; Neurons; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rats; Rats, Zucker; Rimonabant; Thinness; Time Factors | 2006 |
Rimonabant: more than an anti-obesity drug?
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Arthritis; Humans; Hyperalgesia; Inflammation; Obesity; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Arthritis, Experimental; Body Weight; Edema; Female; Freund's Adjuvant; Hot Temperature; Hyperalgesia; Inflammation; Joints; Nitric Oxide; Obesity; Pain Measurement; Pain Threshold; Piperidines; Pyrazoles; Rats; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Touch | 2007 |
Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
Topics: Adult; Appetite Depressants; Cannabinoid Receptor Modulators; Female; Fertility; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant | 2007 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Exercise; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2007 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; PPAR gamma; Pyrazoles; Rimonabant; Weight Loss | 2007 |
Rimonabant in obese patients with type 2 diabetes.
Topics: Depression; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2007 |
Cardiometabolic risk modification: current trends and emerging therapies.
Topics: Adipose Tissue; Antihypertensive Agents; Appetite; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Obesity; Physician Assistants; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Assessment; Risk Factors; Weight Gain | 2006 |
[Endocannabinoids: therapeutic perspectives in chronic liver diseases].
Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2007 |
The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Water; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Eating; Endocannabinoids; Gene Expression Regulation, Enzymologic; Lipid Metabolism; Male; Metabolism; Obesity; Oleic Acids; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Stearoyl-CoA Desaturase; Time Factors | 2008 |
Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.
Topics: Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Obesity; Piperidines; Pyrazoles; Rimonabant | 2007 |
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.
Topics: Animals; Cannabinoid Receptor Antagonists; Fatty Liver; Inflammation; Liver; Male; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA; Tumor Necrosis Factor-alpha | 2007 |
Effects of combined oleoyl-estrone and rimonabant on overweight rats.
Topics: Animals; Anti-Obesity Agents; Appetite; Blood Glucose; Cholecystokinin; Cholesterol; Drug Synergism; Drug Therapy, Combination; Eating; Energy Metabolism; Estrone; Fatty Acids, Nonesterified; Ghrelin; Glucagon-Like Peptide 1; Insulin; Leptin; Male; Obesity; Oleic Acids; Overweight; Peptide Hormones; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Triglycerides | 2007 |
[A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)].
Topics: Appetite Depressants; Cannabinoid Receptor Antagonists; Drug Approval; Germany; Humans; Insurance, Pharmaceutical Services; Life Style; Metabolic Syndrome; National Health Programs; Obesity; Piperidines; Pyrazoles; Quality of Life; Rimonabant | 2006 |
Panel advises against rimonabant approval.
Topics: Advisory Committees; Anti-Obesity Agents; Drug Approval; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; United States | 2007 |
A call to action: new treatment options provide even more reasons to intervene in tobacco dependence.
Topics: Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Obesity; Piperidines; Prevalence; Pyrazoles; Quinoxalines; Rimonabant; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline | 2007 |
Management of obesity in patients with peripheral arterial disease.
Topics: Anti-Obesity Agents; Bariatric Surgery; Body Composition; Body Mass Index; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Humans; Life Style; Obesity; Peripheral Vascular Diseases; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Tomography, X-Ray Computed | 2007 |
Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.
Topics: Adiponectin; Adult; Blood Glucose; Fatty Liver; Female; Humans; Insulin; Lipids; Liver; Mitochondria, Liver; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Severity of Illness Index; Treatment Outcome | 2007 |
The safety of obesity drugs.
Topics: Appetite Depressants; Humans; Mood Disorders; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2007 |
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
Topics: Adiponectin; Animals; Body Weight; Disease Models, Animal; Eating; Kidney; Kidney Failure, Chronic; Lipids; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Survival Analysis | 2007 |
Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice.
Topics: Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eating; Fasting; Mice; Obesity; Oxyntomodulin; Peptide Fragments; Peptide YY; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome | 2008 |
Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.
Topics: Adenoma; Anti-Obesity Agents; Apoptosis; Carcinoma; Cell Transformation, Neoplastic; Colorectal Neoplasms; Dronabinol; Drug Inverse Agonism; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2008 |
[New drugs; rimonabant].
Topics: Appetite Regulation; Cardiovascular Diseases; Depression; Diet, Reducing; Energy Intake; Humans; Lipids; Lipogenesis; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss | 2007 |
Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Topics: Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diet, Reducing; Exercise; Heart Diseases; Humans; Metabolic Diseases; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Safety | 2008 |
[Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].
Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Depression; Drug Approval; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss | 2007 |
Efficacy and safety of the weight-loss drug rimonabant.
Topics: Anti-Obesity Agents; Depression; Depressive Disorder, Major; Humans; Obesity; Patient Selection; Piperidines; Pyrazoles; Rimonabant; Suicide | 2008 |
Efficacy and safety of the weight-loss drug rimonabant.
Topics: Anti-Obesity Agents; Depression; Depressive Disorder, Major; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant | 2008 |
[The endocannabinoid system and treatment of obesity].
Topics: Animals; Anti-Obesity Agents; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss | 2008 |
Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer".
Topics: Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Antineoplastic Agents; Carcinoma; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Humans; Mice; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors | 2008 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Life Style; Myocardial Infarction; Obesity; Pioglitazone; Piperidines; Platelet Aggregation Inhibitors; Prediabetic State; Pyrazoles; Ramipril; Rimonabant; Risk Assessment; Thiazolidinediones; Triglycerides; Weight Loss | 2008 |
[Rimonabant (Acomplia)].
Topics: Anti-Obesity Agents; Drug Interactions; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
Leptin-regulated endocannabinoids are involved in maintaining food intake.
Topics: Animals; Appetite Regulation; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Cerebellum; Eating; Endocannabinoids; Female; Food; Glycerides; Hypothalamus; Leptin; Lipoprotein Lipase; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; Phospholipase D; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cannabinoid; Receptors, Drug; Receptors, Leptin; Rimonabant; Signal Transduction | 2001 |